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 Prions are the causative agents of a group of fatal neurodegenerative diseases known as 
transmissible spongiform encephalopathies.  Prions are unique in that disease is initiated when 
the normal prion protein (PrPC) undergoes a conformational change and propagates through a 
process of templated conversion to an infectious, misfolded, isoform (PrPRES, PrPCWD, or PrPSc) 
which can assemble into oligomers and amyloid fibrils.  Disease is associated with prion 
accumulation in the central nervous system, causing the pathologic lesions of neurodegeneration, 
white matter spongiosis, and a reactive astrogliosis.  Previous work has demonstrated the process 
of prion propagation and disease pathogenesis can be influenced by conversion cofactors, 
inhibitors, and biologic systems.    
 Heat shock proteins have been shown to protect against the toxic disease effects of 
denatured and aggregated proteins in several models of neurodegenerative diseases including 
Alzheimer’s disease, Parkinson’s disease, and spinocerebellar ataxia.  In this dissertation, I 
investigated if  heat shock protein 72 (HSP72) expression in neurons could protect against prion 
disease-associated pathology through a cell culture and mouse model of murine-adapted scrapie 
strain RML.  In contrast to the role in other neurodegenerative diseases, HSP72 did not alter the
prion disease course or amount of prion conversion in either disease model.   
 Chronic wasting disease (CWD) is a naturally occurring, horizontally transmitted prion 
disease affecting wild and captive cervid populations that is rapidly expanding into new states 
and countries.  Studies investigating the distribution of PrPCWD during early subclinical CWD 
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infection have detected prions in the oropharyngeal lymphoid tissues as early as 1.5 months; 
however, the complete tissue distribution of PrPCWD immediately following prion exposure and 
the chronological progression of prion tissue accumulation remains unknown.  Here, I show 
prions initially accumulate in the oropharyngeal lymphoid tissues following mucosal exposure 
and rapidly disseminate to all systemic lymphoid tissues prior to neuroinvasion.  These findings 
will help better understand the early pathogenesis of CWD prior to clinical disease and 
potentially identify therapeutic targets.   
 Prion disease diagnosis relies on demonstration of the misfolded isoform by 
immunodetection, amyloid seeding assays, or animal bioassays, all assays which may require 
separate sample preparations precluding examination by multiple tests.  To address this 
limitation, I developed a new technique to detect PrPCWD amyloid seeding in fixed paraffin-
embedded (FPE) tissues by real-time quaking induced conversion (RT-QuIC).  FPE RT-QuIC 
proved to be more sensitive than IHC for prion detection and the use of RT-QuIC amyloid 
formation kinetics yielded a semi-quantitative estimate of the prion burden in samples without 
the cost and time of animal bioassays. 
 The normal cellular prion protein resides in cell membrane lipid rafts, which has been 
shown to be a site of pathogenic conversion.  Previous in vitro assays have highlighted the ability 
of lipids to promote prion formation but knowledge is limited regarding the capacity of lipids to 
inhibit prion formation.  Here, I show endogenous polar brain lipids directly inhibit prion 
amyloid formation in RT-QuIC in a dose-dependent manner.  This work is the first to identify an 
inhibitory role of lipids and suggests the prion conversion process is influenced by a balance of 
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 Prion diseases, or transmissible spongiform encephalopathies (TSEs), are a collection of 
unique, uniformly fatal, neurodegenerative diseases that affect humans and animals.  Originally 
classified as “slow viruses”, these diseases are caused by an unconventional pathogen, a 
misfolded protein, and result in central nervous system neuropathology characterized by neuropil 
vacuolation (spongiosis), neuronal degeneration, and a reactive gliosis (1,2).  The first identified 
TSE was scrapie in sheep, initially described in the 18th century (3,4).  Currently, animal TSEs 
have expanded to include bovine spongiform encephalopathy (BSE), transmissible mink 
encephalopathy (TME), feline spongiform encephalopathy (FSE), and chronic wasting disease 
(CWD) (2).  TSEs have been clinically recognized in humans since the early 20th century when 
Hans Gerhard Creutzfeldt and Alfons Maria Jakob described a progressive neurological disorder, 
later named Creutzfeldt-Jakob disease (CJD) (5).  Additional human TSEs that have emerged 
through transmissibility observations include Kuru in the Fore tribe of New Guinea and variant 
Creutzfeldt-Jakob disease (2).  Genetic-origin prion diseases also include fatal familial insomnia 
and Gerstmann-Straussler-Sheinker syndrome (2).   
 The studies described in this proposal are framed within the context of the protein-only 
hypothesis.  Unlike the dogma of DNA to RNA to protein established by Watson and Crick, the 
infectious agent causing prion diseases is widely accepted to be a protein devoid of genetic 
material (6,7).  Studies characterizing the unique properties of prions were performed on the 
prototypic TSE, scrapie.  Initial studies established the infectious nature of scrapie by 
successfully transmitting the disease to naïve sheep following a long incubation time, greater 
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than 14 months, leading to the classification of a slow virus (1,8).  Studies performed by Alper 
and Gordon to characterize the scrapie infectious agent established it was resistant to formalin, 
heat, and UV inactivation, treatments known to inactivate viruses and bacteria (9-11).  Due to 
these unique properties, multiple theories were proposed regarding the nature of the scrapie agent 
including a protein, polysaccharide, or membrane fragment absent of nucleic acid (12).  In 1982, 
Stanley Prusiner isolated and purified the scrapie agent, characterized it as a partially protease-
resistant protein, and proposed the term “small proteinaceous infectious protein”, or prion, for 
this unique pathogen (13-15).   
The protein-only hypothesis proposes the infectious prion is a misfolded isoform of the 
normal cellular prion protein, PrPC, and propagates by post-translational templated conversion of 
the α-helical host protein to an abnormal conformation characterized by increased -sheet 
content (7,16-18).  Once the abnormal conformation is adopted, the protein becomes resistant to 
detergents and protease digestion, and can assemble into oligomers, amyloid fibrils, and 
aggregates (19,20).  Of these different protein formations, prion oligomers have been identified 
as containing the greatest toxic activity and amyloid aggregates may potentially serve a 
protective function by sequestering oligomers (21).  The exact mechanism of prion cytotoxicity 
remains unknown, however it has been proposed that oligomers can interact with and disrupt cell 
membranes (19).  In this dissertation, the term PrPRES is used to describe the infectious misfolded 
prion protein in general while PrPSc is used to refer to scrapie prions and PrPCWD used to refer to 
CWD prions.  
The protein-only hypothesis has been investigated in the pathogenesis of other protein 
misfolding neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease 
(PD), Amyotrophic lateral sclerosis (ALS), and polyglutamine (polyQ) repeat diseases (22,23).  
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These diseases also feature host protein misfolding, aggregation, and associated 
neurodegeneration (23).  Despite recent studies demonstrating the respective disease-associated 
alternative protein conformations, like tau in AD and α-synuclein in PD, can initiate disease in 
transgenic mouse models, the likelihood of disease transmission remains low (24-26).  
Nevertheless, the similarities in protein-misfolding propagation between these diseases can 
provide insights into toxic mechanisms and pathogenesis.   
 
The cellular prion protein, PrPC 
 
 The normal cellular prion protein, PrPC, is encoded by the single-copy PRNP gene and 
the protein sequence is highly conserved with greater than 90% homology among species 
(27,28).  In humans, it is transcribed as a 253 amino acid polypeptide and post-translational 
modifications include removal of the N-terminal and C-terminal signal sequences that in vivo 
traffic the protein from the endoplasmic reticulum to lipid rafts in the outer cell membrane 
(2,19).  The protein structure is characterized by a disordered N-terminal domain (NTD) that 
contains a proline and glycine rich “pseudorepeat” and four octapeptide repeats, which is 
separated from the structured C-terminal domain (CTD) by a short hydrophobic region (2,28).   
The structured C-terminal domain contains a two -sheets and three α-helices and is the region 
that takes on the characteristic conformation change by acquiring an increase in -sheets during 
prion disease (28).  The function of PrPC has been associated with signal transduction, cationic 
metal binding, synapse transmission, and apoptosis, however its exact role is unknown as PrPC 
knockout mice display minimal pathology or functional deficits (29-31).   
 The functional PrPC protein is located in the outer lipid bilayer of the cell membrane by a 
GPI anchor where it resides in detergent insoluble lipid rafts, a location that has been shown to 
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influence PrPRES formation and propagation (32-34).  Cell culture and transgenic mouse studies 
established the CTD GPI anchor is not required for PrPRES formation but is necessary for disease 
propagation between cells and pathology (35).  Without the GPI anchor, anchorless PrPRES 
favored large amyloid accumulations in mice without the formation of smaller, oligomer and 
fibril forms and mice did not display clinical disease (36).  Additionally, alterations in the lipid 
bilayer composition or disruption of lipid rafts decreased PrPC concentration at the cell surface 
which resulted in decreased PrPRES (37,38).  These studies highlight the importance of the lipid 
bilayer and lipid raft location as determined by the GPI anchor in the pathogenesis of prion 
disease.   
 
Perspectives on prion propagation adopted in this dissertation: 
 This thesis seeks to address several unanswered questions on prion propagation and 
pathogenesis at the cellular and whole-organism level.  First, I examine how a natural cellular 
system, the heat shock response, which functions to prevent protein denaturation and 
aggregation, influences prion propagation.  Second, the propagation and tissue distribution of 
prions during early CWD pathogenesis is investigated in the natural host.  In the process of this 
study, a new technique was developed that allows detection and semi-quantitative estimation of 
tissue prion burdens by real-time quaking induced conversion (RT-QuIC) in fixed paraffin-
embedded tissues.  Lastly, the influence of brain-derived lipids on RT-QuIC prion propagation is 




Chaperone proteins and prion propagation:  
 The maintenance of correct protein structure is a complex process.  Bacteria and 
eukaryotic cells have evolved protein quality-control systems of molecular chaperones, including 
the heat shock proteins, that protect against protein unfolding or misfolding as a result of stress 
or ageing (39,40).  In eukaryotes one of the major heat-shock protein families is a group of 70 
kDa mass proteins, known as HSP70s, with the main stress-inducible member being HSP72 
along with its co-chaperone HSP40 (41,42).  In prokaryotes the main stress inducible heat shock 
protein is HSP104 while the HSP70 family plays a more accessory role (42).  During periods of 
cellular stress brought on by environmental conditions such as elevated temperatures or hypoxia, 
these proteins function to maintain proteostasis in an ATP-dependent manner by refolding 
misfolded proteins and targeting damaged and unfolded proteins to the ubiquitin-proteosome 
pathway or lysosomes for degradation (39,40).     
The common features of protein misfolding and aggregation in neurodegenerative 
diseases have led to investigations of heat shock proteins as potential therapeutic targets (43).  
Heat shock proteins have been found to co-localize with aggregates and inclusion bodies found 
in protein-misfolding diseases including Alzheimer’s disease, Parkinson’s disease, and polyQ 
protein diseases, suggesting they are able to interact with these proteins (39).  Cell culture and 
transgenic mouse studies have established a correlation between increasing HSP72 expression 
and decreased respective protein accumulations (44-47).  Proposed mechanisms for HSP72 
neuroprotection include stabilizing the native protein structure to prevent the initial misfolding or 
stabilizing misfolded intermediates to promote the on-pathway formation of fibrils and 
aggregates over toxic oligomeric forms (39).  Extracellular HSP72 may also activate microglia 
promoting degradation of extracellular aggregates (48,49).   
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The interaction between heat shock proteins and prion propagation has been best studied 
in yeast.  HSP104, the major inducible chaperone, has a paradoxical relationship with regards to 
prion propagation in yeast: it has been shown to be both a crucial cofactor for prion formation 
and “cure” prion disease by breaking up prion amyloid deposits (50,51).  In fact, these functions 
are not mutually exclusive and are part of a spectrum of HSP104 prion-disaggregase activity 
where wild-type expression levels of HSP104 breaks down prion amyloid aggregates into 
smaller fragments that nucleate additional prion formation and HSP104 over-expression can 
disaggregate enough amyloid to “cure” cells (52,53).  In contrast to yeast, the role of heat shock 
proteins in mammalian prion diseases remains largely unknown.  A single study suggested 
HSP72 protects against prion cellular degeneration in vitro, however, additional research is 
needed to characterize the role of heat shock proteins in vivo (54).     
 
Chronic wasting disease 
 Chronic wasting disease (CWD) is a naturally occurring TSE that affects both 
nondomestic and domestic cervid species, including white-tailed deer, mule deer, wapiti, moose, 
and reindeer (55).  CWD was first identified in a captive herd of mule deer in Fort Collins, CO in 
1967 and classified as a spongiform encephalopathy in the 1980s (56,57).  Since its 
identification, CWD has expanded to 24 states, two Canadian provinces, The Republic of Korea, 
and most recently a wild reindeer in Norway (58-60).  Disease prevalence in affected regions has 
been reported as high as 30% in wild populations and up to 80% in captive populations (61).  
Clinical signs of CWD include primarily progressive weight loss and variable difficulty 
swallowing, ataxia and head tremors, polydipsia, and polyphagia (55,56,62).  Histologic lesions 
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of neuronal degeneration, astrocytosis, and amyloid plaques of PrPCWD are similar to those 
observed in other TSEs (63).   
 CWD presents a particular challenge due to its uniquely efficient horizontal transmission 
(30,55).  Natural CWD transmission is presumed to occur through direct or indirect 
environmental exposure via the oral and/or aerosol routes to contaminated excreta such as saliva, 
feces, and urine (64-68).  Once established in the environment, CWD has been demonstrated to 
persist for multiple years, potentially through complexing with soil (67,69,70).  Although not 
considered a major route of spread, vertical transmission of CWD has been described in 
offspring from infected dams (71).   
 Similar to other prion diseases, like scrapie and vCJD, CWD disease progression is 
influenced by the primary sequence of the PRNP gene of the host animal.  Lower disease 
incidence and a prolonged disease course are reported with the following polymorphisms in 
cervids:  white-tailed deer are G96S and Q95H, elk M132L; and mule deer S225F (72-74).  The 
alternate alleles are reported to occur with less frequency in cervids, comprising less than 25% of 
populations (58).  The PRNP genotype not only impacts prion disease progression but has also 
been reported to influence the development of CWD prion strains (75).    
 
Prion disease progression in the host 
 Insights into the sequence of disease progression in TSEs following oral exposure are 
derived from investigations of the prototypic TSE, scrapie.  Following oral prion exposure there 
are three proposed phases of disease: first, mucosal uptake and drainage to gastrointestinal-
associated lymphoid tissue (GALT); second, systemic lymphoid spread; and last, neuro-invasion 
(76).  In scrapie, the earliest prions were detected in GALT including oropharyngeal lymphoid 
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tissues (tonsil, retropharyngeal lymph nodes), jejunum, and ileum, with subsequent spread to 
systemic lymphoid tissues as disease progressed (76).  This early lymphoid accumulation of 
prions has proven essential for neuroinvasion as blockade of lymphoid drainage to regional 
lymph nodes or disruption of Peyer’s patches delayed PrPSc deposition in nervous tissues 
following oral inoculation (77,78).  Neuroinvasion is proposed to occur at peripheral nerves 
enervating lymphoid tissues or the enteric nervous system and. In scrapie, was detected in the 
enteric nervous system prior to trafficking to brainstem  (79).  Following neuroinvasion at 
peripheral lymphoid tissues, prions undergo retrograde transport through the sympathetic and 
parasympathetic nerves to the central nervous system (80,81).   
Although investigations of sequential disease progression are not possible in human 
TSEs, variant-CJD also displays accumulation in lymphoid tissues in addition to nervous tissues 
(82-84).   Investigations of disease progression in CWD have identified PrPCWD accumulation in 
lymphoid tissues during the pre-clinical period, suggesting a disease pathogenesis similar to 
scrapie (85,86).  However, studies of the earliest time period post-CWD exposure and 
chronological tissue propagation of PrPCWD in the cervid host are lacking and vital to 
identification of pre-clinical therapeutic targets.   
 
Detection of prion disease 
 To accurately evaluate TSE disease progression, sensitive diagnostic techniques are 
required to identify PrPCWD during the pre-clinical period when there potentially is a low prion 
burden in tissues.  The diagnosis of prion disease relies on identification of the disease-
associated misfolded prion conformational state, either through immunodetection, or amyloid 
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detection assays.  Traditionally, immunohistochemistry and/or western blot and animal bioassays 
have been considered the gold standards of prion detection (87).   
Immunodetection assays 
 Conventional diagnosis of prion disease via antibody immunodetection in western 
blotting and immunohistochemistry relies on demonstration of a proteinase-resistant fragment, 
measuring 27-30 kDa in western blotting, which is associated with disease (2).  
Immunohistochemistry protocols rely on formic acid or proteinase-K digestion to remove PrPC 
from tissues leaving PrPRES and sensitivities approach 100% (88,89).  Western blotting also 
provides information regarding the distribution of prion glycosylation patterns in samples (90).  
Limitations of immunodetection methods include false negative results due to harsh proteolytic 
treatments that remove protease-sensitive prion forms or prion burdens below detection 
thresholds (90-92).   
Amyloid seeding assays 
In vitro assays have been developed to amplify small prion amounts in samples from 
early disease time points and in excreta when the prion burden could potentially be below the 
threshold of detection by traditional assays.  These assays, including serial protein-misfolding 
cyclic amplification (sPMCA), amyloid seeding assay (ASA), and real-time quaking induced 
conversion (RT-QuIC), rely on the conversion of PrPC substrate to the disease-specific 
conformation (93-95).   In sPMCA, the PrPC substrate is in the form of brain homogenate derived 
from transgenic mice and prion seeds are amplified by alternating cycles of templated fibril 
elongation and sonication (95).  Prion-induced amplified products are detected through western 
blotting.  In comparison, RT-QuIC employs prion templated conversion of bacterially-produced 
recombinant PrPC substrate into amyloid structures (Figure I.1) (94).  Repeated cycles of 
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shaking, or quaking, accelerates the amyloid formation reaction by breaking formed amyloid 
fibrils into smaller seeds that propagate the seeded conversion.  Prion amyloid formation is 
monitored in real-time with thioflavin T dye binding and fluorescence emission spectral shift that 
is recorded by a fluorometer (96).     
 
Figure I.1 Diagram of the RT-QuIC reaction 
Bacterially-produced recombinant PrPC substrate is converted into amyloid fibrils by prion-
seeded templated conversion.  Amyloid formation is measured in real-time by thioflavin T (ThT) 
binding to amyloid fibrils causing ashift in fluorescence spectral emission.     
 
 RT-QuIC has successfully been applied to the detection of prions in complex body fluids 
and tissues, including brain, lymph nodes, saliva, urine, cerebrospinal fluid, and nasal brushings 
with sensitivities of 70-100% and specificities of 96-98% when evaluated in a diagnostic setting 
(97-104).  In addition to the sensitive detection of PrPRES in samples, the real-time analysis of 
amyloid formation kinetics in RT-QuIC has been applied to semi-quantitatively estimate the 
prion burden in a sample (105).  This is achieved through comparison of prion amyloid 
formation rates or end-point dilutions with those of known animal bioassayed materials 
(105,106).   
 One limitation of prion diagnostics is the requirement of separate sample types for 
individual assays: formaldehyde-fixed tissue for immunohistochemistry and frozen tissue 
homogenates for western blotting and RT-QuIC.  The use of separate samples creates potential 
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disparate assay results due to variable PrPRES deposition and assay sensitivities.  In this 
dissertation, a new technique for detection and quantification of prions in fixed paraffin-
embedded tissues is described. 
 
Prion conversion cofactors 
In the context of the protein-only hypothesis, research has focused on identifying 
cofactors that facilitate conversion from PrPC to infectious PrPRES.  To date, RNA and lipids, in 
particular the anionic lipid phosphatidylethanolamine, have been identified as cofactors capable 
of promoting PrPRES formation from bacterially produced recombinant PrPC in vitro (107-109).  
In contrast to amyloidogenic cofactors, screening assays to identify prion therapeutics have 
detected molecules, both endogenous and pharmacologic origin, that inhibit amyloid formation 
in cell culture systems (110).  The RT-QuIC amyloid seeding reaction is variably inhibited at 
high sample concentrations, such as 10-1 to 10-3, but takes place following dilution, presumably 
due to dilution of inhibitors (84,105,111).  The identity of these endogenous amyloid formation 
inhibitors in RT-QuIC remains unknown.   
 
Questions on prion disease addressed in this dissertation:  
This dissertation seeks to answer several questions regarding prion disease progression, 
including: (1) can a natural protein quality-control system, the heat shock response, be used to 
mitigate prion pathogenicity and disease progression; (2) what is the tissue distribution and 
chronological progression of prion accumulation during early CWD infection in the natural 
cervid host; (3) can endogenous molecules in brain homogenates inhibit or regulate prion 
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amyloid formation in RT-QuIC?  As part of these studies, a new technique for identification and 
quantification of prions in fixed paraffin-embedded tissues was developed and described.   
 
Dissertation research:  
 The above background on prion disease pathogenesis and propagation provide the 
foundation on which the research in this dissertation is based.  The first objective investigated the 
ability of the heat shock system, specifically HSP72, to ameliorate prion-associated 
neurodegeneration.  I hypothesized the expression of HSP72 in neurons could prevent PrPSc 
conversion, aggregation, and protect against prion-associated cytotoxicity.  These studies were 
carried out in a neuroblastoma (N2a) cell line and transgenic C57Bl/6 mice engineered to 
constitutively express HSP72.  HSP72-expressing cells and mice were inoculated with mouse-
adapted scrapie (RML) and evaluated for disease progression as compared to wild-type controls.  
I found that unlike literature demonstrating HSP72 protected against cytotoxicity in animal 
models of protein misfolding diseases, HSP72 neuronal expression did not alter disease 
pathogenesis in vitro or in vivo.   
 There is limited knowledge regarding the site of entry of CWD prions and early pathways 
of PrPCWD tissue dissemination prior to neuroinvasion.  Knowledge of such disease progression 
is vital to understanding how CWD is transmitted so efficiently and developing preclinical 
therapeutic strategies.  Therefore, the second objective of this dissertation was to evaluate the 
distribution of PrPCWD in a natural host, white-tailed deer, during the early stages of disease.  I 
hypothesized PrPCWD tissue distribution would be influenced by exposure route and would have 
a lymphoid replication phase prior to neuroinvasion.  White-tailed deer were exposed to CWD 
by either a mucosal (oral and oro-nasal) or intravenous (IV) route.  IV-exposed deer were 
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evaluated for PrPCWD distribution at 15 minutes or 3 days post-exposure while mucosal-exposed 
deer were evaluated at 15 minutes, 3 days, and monthly from 1 to 4 months.  PrPCWD tissue 
distribution was evaluated by RT-QuIC and tyramide-signal amplification. 
 The requirement of separate tissue sample types, formaldehyde-fixed and frozen 
homogenates, for prion detection can create disparate PrPRES detection results due to variable 
prion deposition or limit retrospective studies when only paraffin-embedded samples are 
available.  In addition, the estimation of tissue prion burdens are restricted to costly and time-
consuming animal bioassays or cell-culture assays which can be precluded by sample type or 
lack of PrPC and sample compatibility.  To overcome these limitations, I developed a new 
technique that combined traditional histologic methodologies and RT-QuIC to detect PrPCWD in 
fixed paraffin-embedded (FPE) tissues.  FPE RT-QuIC amyloid amplification kinetics were used 
to provide semi-quantitative estimations of the prion titer in tissues.   
 During development of FPE RT-QuIC methodology, I observed detection of prion-
seeded amyloid seeding at high concentrations, in direct contrast to previous observations. 
Therefore, the fourth objective of this dissertation was to identify the amyloid formation 
inhibitors present in brain homogenates using RT-QuIC.  I hypothesized endogenous lipids 
present in brain homogenates inhibited the amyloid formation reaction and investigated this 
activity with biochemical lipid extraction protocols and RT-QuIC experiments.  The results of 
this objective will provide a basis for future investigations into the biologic relevance of the 
identified inhibitors.   
 The results of this work contribute to the knowledge of prion pathogenesis in multiple 
areas including heat shock proteins, CWD pathogenesis in the natural host, and novel 
identification of prion amyloid formation inhibitors, as well as development of an enhanced 
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PrPRES detection method with experimental and diagnostic applications.  In these ways, this work 









1. Sigurdsson, B. (1954) Rida, a chronic encephalitis of sheep. . The British veterinary 
journal, 341-354 
2. Prusiner, S. B. (1998) Prions. Proc Natl Acad Sci U S A 95, 13363-13383 
3. Besnoit, C. a. M. C. (1898) Note sur les lesions nerveuses de la tremblante du mouton. 
Rev Vet, 397-400 
4. Wang, F., and Ma, J. (2013) Role of lipid in forming an infectious prion? Acta Biochim 
Biophys Sin (Shanghai) 45, 485-493 
5. Zabel, M. D., and Reid, C. (2015) A brief history of prions. Pathog Dis 73, ftv087 
6. Watson, J. D., and Crick, F. H. (1953) Molecular structure of nucleic acids; a structure 
for deoxyribose nucleic acid. Nature 171, 737-738 
7. Soto, C., and Castilla, J. (2004) The controversial protein-only hypothesis of prion 
propagation. Nature medicine 10 Suppl, S63-67 
8. Cuille J.; Chelle PL. (1938) Investigations of scrapie in sheep. Vet Med 34, 417-418 
9. Latarjet, R., Muel, B., Haig, D. A., Clarke, M. C., and Alper, T. (1970) Inactivation of the 
scrapie agent by near monochromatic ultraviolet light. Na ure 227, 1341-1343 
10. Gordon, W. S. (1946) Advances in veterinary research. The Veterinary record 58, 516-
525 
11. Alper, T., Haig, D. A., and Clarke, M. C. (1966) The exceptionally small size of the 
scrapie agent. Biochemical and biophysical research communications 22, 278-284 
12. Alper, T., Cramp, W. A., Haig, D. A., and Clarke, M. C. (1967) Does the agent of scrapie 
replicate without nucleic acid? Nature 214, 764-766 
13. Prusiner, S. B. (1982) Novel proteinaceous infectious particles cause scrapie. Scienc  
216, 136-144 
14. Prusiner, S. B., Bolton, D. C., Groth, D. F., Bowman, K. A., Cochran, S. P., and 
McKinley, M. P. (1982) Further purification and characterization of scrapie prions. 
Biochemistry 21, 6942-6950 
15. Bolton, D. C., McKinley, M. P., and Prusiner, S. B. (1982) Identification of a protein that 
purifies with the scrapie prion. Science 218, 1309-1311 
16. Pan, K. M., Baldwin, M., Nguyen, J., Gasset, M., Serban, A., Groth, D., Mehlhorn, I., 
Huang, Z., Fletterick, R. J., Cohen, F. E., and et al. (1993) Conversion of alpha-helices 
into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad 
Sci U S A 90, 10962-10966 
17. Weissmann, C. (1991) A 'unified theory' of prion propagation. Nature 352, 679-683 
18. Caughey, B. W., Dong, A., Bhat, K. S., Ernst, D., Hayes, S. F., and Caughey, W. S. 
(1991) Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water 
by infrared spectroscopy. Biochemistry 30, 7672-7680 
19. Caughey, B., Baron, G. S., Chesebro, B., and Jeffrey, M. (2009) Getting a grip on prions: 
oligomers, amyloids, and pathological membrane interactions. Annual review of 
biochemistry 78, 177-204 
20. McKinley, M. P., Bolton, D. C., and Prusiner, S. B. (1983) A protease-resistant protein is 
a structural component of the scrapie prion. Cell 35, 57-62 
21. Silveira, J. R., Raymond, G. J., Hughson, A. G., Race, R. E., Sim, V. L., Hayes, S. F., and 
Caughey, B. (2005) The most infectious prion protein particles. Nature 437, 257-261 
16 
 
22. Olanow, C. W., and Prusiner, S. B. (2009) Is Parkinson's disease a prion disorder? Proc 
Natl Acad Sci U S A 106, 12571-12572 
23. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. 
Nature reviews. Neuroscience 4, 49-60 
24. Peeraer, E., Bottelbergs, A., Van Kolen, K., Stancu, I. C., Vasconcelos, B., Mahieu, M., 
Duytschaever, H., Ver Donck, L., Torremans, A., Sluydts, E., Van Acker, N., Kemp, J. 
A., Mercken, M., Brunden, K. R., Trojanowski, J. Q., Dewachter, I., Lee, V. M., and 
Moechars, D. (2015) Intracerebral injection of preformed synthetic tau fibrils initiates 
widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol 
Dis 73, 83-95 
25. Luk, K. C., Kehm, V. M., Zhang, B., O'Brien, P., Trojanowski, J. Q., and Lee, V. M. 
(2012) Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly 
progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med 209, 975-986 
26. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J. Q., and Lee, V. 
M. (2012) Pathological alpha-synuclein transmission initiates Parkinson-like 
neurodegeneration in nontransgenic mice. Science 338, 949-953 
27. Wopfner, F., Weidenhofer, G., Schneider, R., von Brunn, A., Gilch, S., Schwarz, T. F., 
Werner, T., and Schatzl, H. M. (1999) Analysis of 27 mammalian and 9 avian PrPs 
reveals high conservation of flexible regions of the prion protein. Journal of molecular 
biology 289, 1163-1178 
28. Surewicz, W. K., and Apostol, M. I. (2011) Prion protein and its conformational 
conversion: a structural perspective. Topics in current chemistry 305, 135-167 
29. Westergard, L., Christensen, H. M., and Harris, D. A. (2007) The cellular prion protein 
(PrP(C)): its physiological function and role in disease. Biochimica et biophysica acta 
1772, 629-644 
30. Aguzzi, A., Sigurdson, C., and Heikenwaelder, M. (2008) Molecular mechanisms of 
prion pathogenesis. Annual review of pathology 3, 11-40 
31. Steele, A. D., Lindquist, S., and Aguzzi, A. (2007) The prion protein knockout mouse: a 
phenotype under challenge. Prion 1, 83-93 
32. Naslavsky, N., Stein, R., Yanai, A., Friedlander, G., and Taraboulos, A. (1997) 
Characterization of detergent-insoluble complexes containing the cellular prion protein 
and its scrapie isoform. The Journal of biological chemistry 272, 6324-6331 
33. Caughey, B., Race, R. E., Ernst, D., Buchmeier, M. J., and Chesebro, B. (1989) Prion 
protein biosynthesis in scrapie-infected and uninfected neuroblastoma cells. Journal of 
virology 63, 175-181 
34. Mange, A., Nishida, N., Milhavet, O., McMahon, H. E., Casanova, D., and Lehmann, S. 
(2000) Amphotericin B inhibits the generation of the scrapie isoform of the prion protein 
in infected cultures. Journal of virology 74, 3135-3140 
35. Priola, S. A., and McNally, K. L. (2009) The role of the prion protein membrane anchor 
in prion infection. Prion 3, 134-138 
36. Chesebro, B., Trifilo, M., Race, R., Meade-White, K., Teng, C., LaCasse, R., Raymond, 
L., Favara, C., Baron, G., Priola, S., Caughey, B., Masliah, E., and Oldstone, M. (2005) 
Anchorless prion protein results in infectious amyloid disease without clinical scrapie. 
Science 308, 1435-1439 
37. Gilch, S., Kehler, C., and Schatzl, H. M. (2006) The prion protein requires cholesterol for 
cell surface localization. Molecular and cellular neurosciences 31, 346-353 
17 
 
38. Gilch, S., Bach, C., Lutzny, G., Vorberg, I., and Schatzl, H. M. (2009) Inhibition of 
cholesterol recycling impairs cellular PrP(Sc) propagation. Cell Mol Life Sci 66, 3979-
3991 
39. Muchowski, P. J., and Wacker, J. L. (2005) Modulation of neurodegeneration by 
molecular chaperones. Nature reviews. Neuroscience 6, 11-22 
40. Lindquist, S. (1986) The heat-shock response. Annual review of biochemistry 55, 1151-
1191 
41. Kiang, J. G., and Tsokos, G. C. (1998) Heat shock protein 70 kDa: molecular biology, 
biochemistry, and physiology. Pharmacol Ther 80, 183-201 
42. Lindquist, S., and Craig, E. A. (1988) The heat-shock proteins. An u Rev Genet 22, 631-
677 
43. Morimoto, R. I., and Santoro, M. G. (1998) Stress-inducible responses and heat shock 
proteins: new pharmacologic targets for cytoprotection. Nature biotechnology 16, 833-
838 
44. Auluck, P. K., Chan, H. Y., Trojanowski, J. Q., Lee, V. M., and Bonini, N. M. (2002) 
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's 
disease. Science 295, 865-868 
45. Klucken, J., Shin, Y., Masliah, E., Hyman, B. T., and McLean, P. J. (2004) Hsp70 
Reduces alpha-Synuclein Aggregation and Toxicity. The Journal of biological chemistry 
279, 25497-25502 
46. Cummings, C. J., Sun, Y., Opal, P., Antalffy, B., Mestril, R., Orr, H. T., Dillmann, W. H., 
and Zoghbi, H. Y. (2001) Over-expression of inducible HSP70 chaperone suppresses 
neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10, 1511-
1518 
47. Shinder, G. A., Lacourse, M. C., Minotti, S., and Durham, H. D. (2001) Mutant Cu/Zn-
superoxide dismutase proteins have altered solubility and interact with heat shock/stress 
proteins in models of amyotrophic lateral sclerosis. The Journal of biological chemistry 
276, 12791-12796 
48. Kakimura, J., Kitamura, Y., Takata, K., Umeki, M., Suzuki, S., Shibagaki, K., Taniguchi, 
T., Nomura, Y., Gebicke-Haerter, P. J., Smith, M. A., Perry, G., and Shimohama, S. 
(2002) Microglial activation and amyloid-beta clearance induced by exogenous heat-
shock proteins. FASEB journal : official publication of the Federation of American 
Societies for Experimental Biology 16, 601-603 
49. Broquet, A. H., Thomas, G., Masliah, J., Trugnan, G., and Bachelet, M. (2003) 
Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains 
correlates with its membrane delivery and release. Th  Journal of biological chemistry 
278, 21601-21606 
50. Kryndushkin, D. S., Engel, A., Edskes, H., and Wickner, R. B. (2011) Molecular 
chaperone Hsp104 can promote yeast prion generation. Genetics 188, 339-348 
51. Sweeny, E. A., and Shorter, J. (2015) Mechanistic and Structural Insights into the Prion-
Disaggregase Activity of Hsp104. Journal of molecular biology  
52. Wegrzyn, R. D., Bapat, K., Newnam, G. P., Zink, A. D., and Chernoff, Y. O. (2001) 
Mechanism of prion loss after Hsp104 inactivation in yeast. Mol Cell Biol 21, 4656-4669 
53. Chernoff, Y. O., Lindquist, S. L., Ono, B., Inge-Vechtomov, S. G., and Liebman, S. W. 
(1995) Role of the chaperone protein Hsp104 in propagation of the yeast prion-like factor 
[psi+]. Science 268, 880-884 
18 
 
54. Resenberger, U. K., Muller, V., Munter, L. M., Baier, M., Multhaup, G., Wilson, M. R., 
Winklhofer, K. F., and Tatzelt, J. (2012) The heat shock response is modulated by and 
interferes with toxic effects of scrapie prion protein and amyloid beta. The Journal of 
biological chemistry 287, 43765-43776 
55. Williams, E. S. (2005) Chronic wasting disease. Veterinary pathology 42, 530-549 
56. Williams, E. S., and Young, S. (1980) Chronic wasting disease of captive mule deer: a 
spongiform encephalopathy. Journal of wildlife diseases 16, 89-98 
57. Williams, E. S., and Young, S. (1982) Spongiform encephalopathy of Rocky Mountain 
elk. Journal of wildlife diseases 18, 465-471 
58. Haley, N. J., and Hoover, E. A. (2015) Chronic wasting disease of cervids: current 
knowledge and future perspectives. Annu Rev Anim Biosci 3, 305-325 
59. ProMED-mail. (2016) Chronic Wasting Disease, Cervid - Europe: (Norway). ProMed-
mail 20160410.4149651 
60. USGS. (2016) Map of Chronic Wasting disease in North America. 
http://www.nwhc.usgs.gov/images/cwd/cwd_map.jpg 
61. Keane, D. P., Barr, D. J., Bochsler, P. N., Hall, S. M., Gidlewski, T., O'Rourke, K. I., 
Spraker, T. R., and Samuel, M. D. (2008) Chronic wasting disease in a Wisconsin white-
tailed deer farm. Journal of veterinary diagnostic investigation : official publication of 
the American Association of Veterinary Laboratory Diagnosticians, Inc 20, 698-703 
62. Sigurdson, C. J., and Miller, M. W. (2003) Other animal prion diseases. Briti h medical 
bulletin 66, 199-212 
63. Williams, E. S., and Young, S. (1993) Neuropathology of chronic wasting disease of 
mule deer (Odocoileus hemionus) and elk (Cervus elaphus nelsoni). Veterinary pathology 
30, 36-45 
64. Denkers, N. D., Hayes-Klug, J., Anderson, K. R., Seelig, D. M., Haley, N. J., Dahmes, S. 
J., Osborn, D. A., Miller, K. V., Warren, R. J., Mathiason, C. K., and Hoover, E. A. 
(2013) Aerosol transmission of chronic wasting disease in white-tailed deer. Journal of 
virology 87, 1890-1892 
65. Mathiason, C. K., Powers, J. G., Dahmes, S. J., Osborn, D. A., Miller, K. V., Warren, R. 
J., Mason, G. L., Hays, S. A., Hayes-Klug, J., Seelig, D. M., Wild, M. A., Wolfe, L. L., 
Spraker, T. R., Miller, M. W., Sigurdson, C. J., Telling, G. C., and Hoover, E. A. (2006) 
Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 
314, 133-136 
66. Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C., and Hoover, E. A. (2009) 
Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PloS 
one 4, e4848 
67. Miller, M. W., Williams, E. S., Hobbs, N. T., and Wolfe, L. L. (2004) Environmental 
sources of prion transmission in mule deer. Emerg Infect Dis 10, 1003-1006 
68. Tamguney, G., Miller, M. W., Wolfe, L. L., Sirochman, T. M., Glidden, D. V., Palmer, 
C., Lemus, A., DeArmond, S. J., and Prusiner, S. B. (2009) Asymptomatic deer excrete 
infectious prions in faeces. Nature 461, 529-532 
69. Johnson, C. J., Phillips, K. E., Schramm, P. T., McKenzie, D., Aiken, J. M., and 
Pedersen, J. A. (2006) Prions adhere to soil minerals and remain infectious. PL S 
pathogens 2, e32 
70. Smith, C. B., Booth, C. J., and Pedersen, J. A. (2011) Fate of prions in soil: a review. J 
Environ Qual 40, 449-461 
19 
 
71. Nalls, A. V., McNulty, E., Powers, J., Seelig, D. M., Hoover, C., Haley, N. J., Hayes-
Klug, J., Anderson, K., Stewart, P., Goldmann, W., Hoover, E. A., and Mathiason, C. K. 
(2013) Mother to offspring transmission of chronic wasting disease in reeves' muntjac 
deer. PloS one 8, e71844 
72. Johnson, C. J., Herbst, A., Duque-Velasquez, C., Vanderloo, J. P., Bochsler, P., Chappell, 
R., and McKenzie, D. (2011) Prion protein polymorphisms affect chronic wasting disease 
progression. PloS one 6, e17450 
73. Johnson, C., Johnson, J., Clayton, M., McKenzie, D., and Aiken, J. (2003) Prion protein 
gene heterogeneity in free-ranging white-tailed deer within the chronic wasting disease 
affected region of Wisconsin. Journal of wildlife diseases 39, 576-581 
74. O'Rourke, K. I., Spraker, T. R., Hamburg, L. K., Besser, T. E., Brayton, K. A., and 
Knowles, D. P. (2004) Polymorphisms in the prion precursor functional gene but not the 
pseudogene are associated with susceptibility to chronic wasting disease in white-tailed 
deer. The Journal of general virology 85, 1339-1346 
75. Duque Velasquez, C., Kim, C., Herbst, A., Daude, N., Garza, M. C., Wille, H., Aiken, J., 
and McKenzie, D. (2015) Deer Prion Proteins Modulate the Emergence and Adaptation 
of Chronic Wasting Disease Strains. Journal of virology 89, 12362-12373 
76. van Keulen, L. J., Vromans, M. E., and van Zijderveld, F. G. (2002) Early and late 
pathogenesis of natural scrapie infection in sheep. APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica 110, 23-32 
77. Prinz, M., Huber, G., Macpherson, A. J., Heppner, F. L., Glatzel, M., Eugster, H. P., 
Wagner, N., and Aguzzi, A. (2003) Oral prion infection requires normal numbers of 
Peyer's patches but not of enteric lymphocytes. The American journal of pathology 162, 
1103-1111 
78. Mabbott, N. A., Young, J., McConnell, I., and Bruce, M. E. (2003) Follicular dendritic 
cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway 
dramatically reduces scrapie susceptibility. Journal of virology 77, 6845-6854 
79. van Keulen, L. J., Schreuder, B. E., Vromans, M. E., Langeveld, J. P., and Smits, M. A. 
(2000) Pathogenesis of natural scrapie in sheep. Archives of virology. Supplementum, 57-
71 
80. Glatzel, M., Heppner, F. L., Albers, K. M., and Aguzzi, A. (2001) Sympathetic 
innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 31, 
25-34 
81. Haik, S., Faucheux, B. A., Sazdovitch, V., Privat, N., Kemeny, J. L., Perret-Liaudet, A., 
and Hauw, J. J. (2003) The sympathetic nervous system is involved in variant 
Creutzfeldt-Jakob disease. Nature medicine 9, 1121-1123 
82. Ironside, J. W., McCardle, L., Horsburgh, A., Lim, Z., and Head, M. W. (2002) 
Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica 110, 79-87 
83. Hill, A. F., Butterworth, R. J., Joiner, S., Jackson, G., Rossor, M. N., Thomas, D. J., 
Frosh, A., Tolley, N., Bell, J. E., Spencer, M., King, A., Al-Sarraj, S., Ironside, J. W., 
Lantos, P. L., and Collinge, J. (1999) Investigation of variant Creutzfeldt-Jakob disease 
and other human prion diseases with tonsil biopsy samples. Lancet 353, 183-189 
84. Wadsworth, J. D., Joiner, S., Hill, A. F., Campbell, T. A., Desbruslais, M., Luthert, P. J., 
and Collinge, J. (2001) Tissue distribution of protease resistant prion protein in variant 
20 
 
Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 
171-180 
85. Fox, K. A., Jewell, J. E., Williams, E. S., and Miller, M. W. (2006) Patterns of PrPCWD 
accumulation during the course of chronic wasting disease infection in orally inoculated 
mule deer (Odocoileus hemionus). The Journal of general virology 87, 3451-3461 
86. Sigurdson, C. J., Williams, E. S., Miller, M. W., Spraker, T. R., O'Rourke, K. I., and 
Hoover, E. A. (1999) Oral transmission and early lymphoid tropism of chronic wasting 
disease PrPres in mule deer fawns (Odocoileus hemionus). The Journal of general 
virology 80 ( Pt 10), 2757-2764 
87. Bolea, R., Monleon, E., Schiller, I., Raeber, A. J., Acin, C., Monzon, M., Martin-Burriel, 
I., Struckmeyer, T., Oesch, B., and Badiola, J. J. (2005) Comparison of 
immunohistochemistry and two rapid tests for detection of abnormal prion protein in 
different brain regions of sheep with typical scrapie. Journal of veterinary diagnostic 
investigation : official publication of the American Association of Veterinary Laboratory 
Diagnosticians, Inc 17, 467-469 
88. Spraker, T. R., O'Rourke, K. I., Balachandran, A., Zink, R. R., Cummings, B. A., Miller, 
M. W., and Powers, B. E. (2002) Validation of monoclonal antibody F99/97.6.1 for 
immunohistochemical staining of brain and tonsil in mule deer (Odocoileus hemionus) 
with chronic wasting disease. Journal of veterinary diagnostic investigation : official 
publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 
14, 3-7 
89. Spraker, T. R., Zink, R. R., Cummings, B. A., Wild, M. A., Miller, M. W., and O'Rourke, 
K. I. (2002) Comparison of histological lesions and immunohistochemical staining of 
proteinase-resistant prion protein in a naturally occurring spongiform encephalopathy of 
free-ranging mule deer (Odocoileus hemionus) with those of chronic wasting disease of 
captive mule deer. Veterinary pathology 39, 110-119 
90. Safar, J. G., Geschwind, M. D., Deering, C., Didorenko, S., Sattavat, M., Sanchez, H., 
Serban, A., Vey, M., Baron, H., Giles, K., Miller, B. L., Dearmond, S. J., and Prusiner, S. 
B. (2005) Diagnosis of human prion disease. Proc Natl Acad Sci U S A 102, 3501-3506 
91. Tzaban, S., Friedlander, G., Schonberger, O., Horonchik, L., Yedidia, Y., Shaked, G., 
Gabizon, R., and Taraboulos, A. (2002) Protease-sensitive scrapie prion protein in 
aggregates of heterogeneous sizes. Biochemistry 41, 12868-12875 
92. Haley, N. J., Mathiason, C. K., Carver, S., Telling, G. C., Zabel, M. D., and Hoover, E. 
A. (2012) Sensitivity of protein misfolding cyclic amplification versus 
immunohistochemistry in ante-mortem detection of chronic wasting disease. The Journal 
of general virology 93, 1141-1150 
93. Colby, D. W., Zhang, Q., Wang, S., Groth, D., Legname, G., Riesner, D., and Prusiner, S. 
B. (2007) Prion detection by an amyloid seeding assay. Proc Natl Acad Sci U S A 104, 
20914-20919 
94. Atarashi, R., Moore, R. A., Sim, V. L., Hughson, A. G., Dorward, D. W., Onwubiko, H. 
A., Priola, S. A., and Caughey, B. (2007) Ultrasensitive detection of scrapie prion protein 
using seeded conversion of recombinant prion protein. Nature methods 4, 645-650 
95. Saborio, G. P., Permanne, B., and Soto, C. (2001) Sensitive detection of pathological 
prion protein by cyclic amplification of protein misfolding. Nature 411, 810-813 
96. LeVine, H., 3rd. (1999) Quantification of beta-sheet amyloid fibril structures with 
thioflavin T. Methods in enzymology 309, 274-284 
21 
 
97. Haley, N. J., Carver, S., Hoon-Hanks, L. L., Henderson, D. M., Davenport, K. A., 
Bunting, E., Gray, S., Trindle, B., Galeota, J., LeVan, I., Dubovos, T., Shelton, P., and 
Hoover, E. A. (2014) Detection of chronic wasting disease in the lymph nodes of free-
ranging cervids by real-time quaking-induced conversion. J urnal of clinical 
microbiology 52, 3237-3243 
98. McGuire, L. I., Peden, A. H., Orru, C. D., Wilham, J. M., Appleford, N. E., Mallinson, 
G., Andrews, M., Head, M. W., Caughey, B., Will, R. G., Knight, R. S., and Green, A. J. 
(2012) Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic 
Creutzfeldt-Jakob disease. Annals of neurology 72, 278-285 
99. Peden, A. H., McGuire, L. I., Appleford, N. E., Mallinson, G., Wilham, J. M., Orru, C. 
D., Caughey, B., Ironside, J. W., Knight, R. S., Will, R. G., Green, A. J., and Head, M. 
W. (2012) Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain 
prion protein using real-time quaking-induced conversion. The Journal of general 
virology 93, 438-449 
100. Henderson, D. M., Denkers, N. D., Hoover, C. E., Garbino, N., Mathiason, C. K., and 
Hoover, E. A. (2015) Longitudinal Detection of Prion Shedding in Saliva and Urine by 
Chronic Wasting Disease-Infected Deer by Real-Time Quaking-Induced Conversion. 
Journal of virology 89, 9338-9347 
101. Zanusso, G., Bongianni, M., and Caughey, B. (2014) A test for Creutzfeldt-Jakob disease 
using nasal brushings. The New England journal of medicine 371, 1842-1843 
102. Haley, N. J., Siepker, C., Walter, W. D., Thomsen, B. V., Greenlee, J. J., Lehmkuhl, A. 
D., and Richt, J. A. (2016) Antemortem Detection of Chronic Wasting Disease Prions in 
Nasal Brush Collections and Rectal Biopsy Specimens from White-Tailed Deer by Real-
Time Quaking-Induced Conversion. Journal of clinical microbiology 54, 1108-1116 
103. Zanusso, G., Monaco, S., Pocchiari, M., and Caughey, B. (2016) Advanced tests for early 
and accurate diagnosis of Creutzfeldt-Jakob disease. Nat Rev Neurol  
104. Henderson, D. M., Manca, M., Haley, N. J., Denkers, N. D., Nalls, A. V., Mathiason, C. 
K., Caughey, B., and Hoover, E. A. (2013) Rapid antemortem detection of CWD prions 
in deer saliva. PloS one 8, e74377 
105. Henderson, D. M., Davenport, K. A., Haley, N. J., Denkers, N. D., Mathiason, C. K., and 
Hoover, E. A. (2015) Quantitative assessment of prion infectivity in tissues and body 
fluids by real-time quaking-induced conversion. The Journal of general virology 96, 210-
219 
106. Wilham, J. M., Orru, C. D., Bessen, R. A., Atarashi, R., Sano, K., Race, B., Meade-
White, K. D., Taubner, L. M., Timmes, A., and Caughey, B. (2010) Rapid end-point 
quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS 
pathogens 6, e1001217 
107. Deleault, N. R., Piro, J. R., Walsh, D. J., Wang, F., Ma, J., Geoghegan, J. C., and 
Supattapone, S. (2012) Isolation of phosphatidylethanolamine as a solitary cofactor for 
prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A 109, 8546-
8551 
108. Deleault, N. R., Lucassen, R. W., and Supattapone, S. (2003) RNA molecules stimulate 
prion protein conversion. Nature 425, 717-720 
109. Wang, F., Wang, X., Yuan, C. G., and Ma, J. (2010) Generating a prion with bacterially 
expressed recombinant prion protein. Science 327, 1132-1135 
22 
 
110. Trevitt, C. R., and Collinge, J. (2006) A systematic review of prion therapeutics in 
experimental models. Brain : a journal of neurology 129, 2241-2265 
111. Mori, T., Atarashi, R., Furukawa, K., Takatsuki, H., Satoh, K., Sano, K., Nakagaki, T., 
Ishibashi, D., Ichimiya, K., Hamada, M., Nakayama, T., and Nishida, N. (2016) A direct 
assessment of human prion adhered to steel wire using real-time quaking-induced 




CHAPTER 1:  






 Heat shock proteins are molecular chaperones that function during periods of stress to 
maintain cellular proteostasis by rescuing denatured proteins and preventing aberrant 
aggregation.  Expression of the major inducible member of the 70 kDa heat shock protein family 
(HSP72), has been shown to protect against the pathologic effects in models of 
neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and 
spinocerebellar ataxia, by decreasing protein aggregation and preventing cytotoxicity.  Prion 
investigations in yeast have illustrated heat shock proteins have disaggregase activity which can 
both propagate prions and “cure” cells, however, the role of heat shock proteins in mammalian 
prion diseases remains unknown.  We investigated this role in vitro by exposing murine 
neuroblastoma cells stably transfected to constitutively express HSP72 (N2a-HSP72) and their 
vector transfected controls to mouse-adapted scrapie (RML) brain homogenate or normal FVB 
mouse brain controls.  Following RML prion exposure, the N2a-V cells exhibited a reduced 
growth rate compared with RML-exposed N2a-HSP72 cells.  However, examination of the prion 
burden by real-time quaking induced conversion revealed no differences between the groups.  
We extended our HSP72 study to in vivo studies by inoculating transgenic C57Bl/6 mice 
engineered to constitutively express HSP72 in neurons or C57Bl/6 control mice with RML 
prions by intracranial or intraperitoneal routes.  We observed no differences in the course of 
prion disease, brain prion accumulation, or pathology between the two mouse strains.  Overall, 






Organisms have cellular protein quality controls mechanisms to maintain proteostasis and 
counteract protein denaturation and aggregation that can occur during periods of stress (1).  One 
of the best characterized systems is a group of molecular chaperones, the heat shock proteins, 
with a member of the 70 kDa protein family (HSP72) being the major stress-inducible protein in 
mammals (1,2).  These proteins are upregulated under control of the HSF1 promotor following 
stress triggers including hypoxia, ischemia, and hyperthermia, and act to refold proteins back to 
functional conformations or target damaged proteins for degradation via the ubiquitin-
proteosome system (1,3).   
Several neurodegenerative diseases share the feature of aberrant protein folding and 
aggregation with prion diseases, including Alzheimer’s disease (AD), Parkinson’s disease, and 
the polyglutamine-repeat disease Huntington’s disease (3,4).  In several of these diseases, the 
expression of molecular chaperones, particularly HSP72, improved disease-related pathogenesis.  
Cell culture studies of AD demonstrated expression of HSP72 decreased tau aggregation and 
rescued neurons from amyloid- associated toxicity (5,6).  HSP72 expression also decreased 
toxicity in drosophila model of α-synuclein-mediated neurodegeneration demonstrated by 
increased cell viability but did not alter protein aggregation levels (7,8).  In vivo models of AD 
and spinocerebellar ataxia have shown that overexpression of HSP72 suppresses clinical disease 
and decreases the levels of pathogenic protein aggregation in the brain (9,10).  These studies 
highlight the protective role HSP72 can play in neurodegenerative diseases and has generated 
discussion regarding its potential as a therapeutic target (11).   
The majority of studies investigating the interactions of heat shock proteins and prions 
are limited to yeast or mammalian cell culture.  In yeast, the major inducible stress protein is 
25 
 
HSP104 and research has illustrated its important disaggregase function in prion pathogenesis 
(12).  HSP104 is required for propagation of prion pathogenesis as it operates to break apart 
prion aggregates and create more seeds to nucleate prion conversion (13,14).  In contrast, 
overexpression of HSP104 can “cure” yeast of prion infection by disaggregating enough prion to 
remove infection (13,15).   
Investigations of HSP72 function in mammalian n vitro models of TSEs have identified 
similarities with other protein misfolding diseases.  Scrapie infection in murine neuroblastoma 
cells disrupts the ability of cells to mount the heat shock response due to increased degradation 
of HSF1, suggesting heat shock proteins are involved in prion pathogenesis (16).  Moreover, a 
follow up investigation found that pharmacologic induction of the heat shock response or 
elevated levels of HSP72 due to co-culture conditions prolonged cell survival of prion-infected 
cells (17). 
Based on literature demonstrating the protective role of HSP72 in protein-misfolding 
diseases, we hypothesized expression of HSP72 could prevent prion-associated pathology.  We 
investigated the protective role of HSP72 in vitro and in vivo using cell culture and mouse-
adapted models of scrapie, by comparing survival and pathology following prion challenge in the 
face of constitutive HSP72 expression in neurons.  In contrast to the function of HSP104 in yeast 
and HSP72 neurodegenerative disease models, we did not observe a positive influence on HSP72 
pathogenesis or survival in cell culture or mice.  Instead, HSP72 expression did not alter the 











Murine neuroblastoma cell culture and infection 
 Murine neuroblastoma cells (N2a) engineered to constitutively express heat shock protein 
72 were kindly provided by Dr. Michael Oglesbee at The Ohio State University.  Briefly, cells 
were stably transfected with a plasmid vector containing the human HSP72 construct driven by 
the -actin promotor (N2a-HSP72) or the empty plasmid vector alone (designated N2a-V) 
(18,19).  Selection of transfected cells was ensured with a neomycin resistance gene.  Cells were 
maintained in Advanced Minimal Essential Media (MEM) (Gibco) supplemented with 10% fetal 
bovine serum (Gibco), 1% penicillin-streptomycin (Gibco), 1% GlutaMax (Thermo Fisher 
Scientific), and 0.8% geneticin (G418) (Thermo Fischer Scientific) selection antibiotic.  Media 
was changed every 4 days and cells were passaged weekly using 0.25% trypsin-EDTA (Gibco) 
to release the cells.   
 N2a cells were exposed to Rocky Mountain Laboratory strain of mouse-adapted scrapie 
(RML) prion brain homogenate or prion-negative FVB normal mouse brain homogenate.  Brain 
homogenate inoculum was diluted to 0.1% in sterile 1xPBS.  One x 105 cells were incubated 
with 100 µL of 0.1% brain inoculum for 30 minutes at room temperature and then plated in one 
well of a 12-well plate at 37°C with 1 mL of prepared media.  Cell culture media was changed 24 
hours after plating.  Cells were observed daily for cell density and cytopathic effect and cell 
Cohorts were harvested at 72 hours post-exposure and counted.  The cell infection experiment 






Real-time quaking induced conversion (RT-QuIC) of cell lysates 
Cell lysis 
 At the time of collection, brain-homogenate exposed cells and control cells were 
passaged as previously described.  One x 105 cells were pelleted by centrifugation at 1,000 x rpm 
and lysed with 100 μL of lysis buffer (5mM EDTA, 150 mM NaCl, 1.0% TritonTM X-100 
[Sigma-Aldrich]).  Cell lysates were subjected to 2 freeze/thaw cycles prior to centrifugation at 
15,000 x rpm to pellet debris.  Supernatants were removed and stored at -80֠ C until RT-QuIC 
analysis.   
RT-QuIC substrate purification:  
 Recombinant truncated Syrian hamster prion protein (SHrPrP), containing residues 90-
231, was purified as previously described (20,21).  BL21 Rosetta (Novagen) Escherichia coli 
containing the truncated protein construct were cultured from a glycerol stock at 37°C in 
lysogeny broth (LB) media with the selection antibiotics kanamycin and chloramphenicol to 
express SHrPrP until the culture optical density at 600 nm (OD600) reached at least 2.5.  E. coli 
cell lysis was carried out using BugbusterTM reagent supplemented with LysonaseTM (EMD 
Biosciences) according to the manufacturer recommended protocol.  Inclusion bodies were 
harvested by centrifugation at 15,000 x g and dissolved in solubilization buffer (8M guanidine 
hydrochloride, 100 mM Na2HPO4) prior to application to NiNTA flow resin (Qiagen) that had 
been previously equilibrated with denaturation buffer (6M guanidine hydrochloride, 100 mM 
Na2HPO4, 10mM Tris, pH 8.0).  The NiNTA resin-SHrPrP was loaded onto a XK16-60 column 
(GE Healthcare) and purified using a Bio-Rad DuoflowTM FPLC.  To induce protein refolding, a 
gradient from denaturation buffer to refolding buffer (100 mM Na2HPO4, 10mM Tris pH 5.5) 
was applied.  Refolding was followed by a gradient from refolding to elution buffer (100mM 
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Na2HPO4, 10 mM Tris, 0.5 M imidazole) and fractions from the elution peak were pooled and 
dialyzed in two changes of buffer (20mM NaH2PO4, pH 5.5) overnight.  Final protein 
concentration was calculated by measuring the A280 and using a coefficient of extinction of 
β5,900 in Beer’s Law.  Purified SHrPrP was stored at 4°C until use.     
RT-QuIC conditions 
 RT-QuIC was performed as previously described (20,22).  Cell lysates were diluted 
1,000-fold and brain homogenates were diluted to the desired concentration in 0.1% sodium 
dodecyl sulfate (SDS)/1xPBS prior to seeding RT-QuIC.  The RT-QuIC reaction was carried out 
by adding β μL of diluted sample to a buffer containing β0mM NaH2PO4, 430mM NaCl, 1.0 
EDTA, 1mM Thioflavin T (ThT) and 0.1 mg/mL SHrPrP in one well of a black, optical-bottom 
96-well plate (Nunc).  RT-QuIC experiments were carried out in a BMG Labtech PolarstarTM 
fluorometer with cycles of 1 minute shaking (700 rpm, double orbital) followed by 1 minute rest, 
repeated for 15 minutes.  ThT fluorescence was read (excitation 450 nm, emission 480 nm, gain 
of 1700) at the conclusion of each 15 minute shake/rest cycle and each well was measured with 
20 flashes per well with an orbital average of 4.  Each RT-QuIC experiment was performed for a 
minimum of 200 cycles or 48 hours.  RT-QuIC amyloid formation was determined to be positive 
if the fluorescence exceeded a threshold determined to be 5 standard deviations above the 
average baseline fluorescence.  RT-QuIC amyloid formation rates in RT-QuIC were analyzed by 
calculating the inverse of the time to threshold.   
 
Animals 
 Transgenic C57BL/6 mice engineered to constitutively express HSP72 in neurons under 
control of the neuron-specific enolase promoter (TgNSE-HSP72) were generated as previously 
described and kindly provided by Dr. Michael Oglesbee, the Ohio State University of Columbus, 
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OH (23).  Mice were bred and maintained at Colorado State University according to protocols 
approved by the Institutional Animal Care and Use committee.  Age-matched C57Bl/6 mice used 
as controls were purchased from Jackson Laboratories (Bar Harbor, ME).   
 
Prion inoculation protocol 
 The prion positive inoculum used was the Rocky Mountain Laboratory strain of mouse-
adapted scrapie (RML), as characterized previously (24).  RML was passaged 5 times through 
FVB mice and a 10% weight/volume brain homogenate was prepared in sterile 1xPBS.  The 
negative control inoculum was a 10% weight/volume normal brain homogenate of FVB mouse 
origin prepared similarly.  Both positive and negative inocula were diluted to a final 
concentration of 0.1% (wt/vol) in sterile PBS containing 100 U/mL penicillin-streptomycin.   
 To study the effect of HSP72 expression on prion trafficking to nervous tissues, we used 
an intraperitoneal (IP) route to mimic peripheral prion exposure.  Six to eight week old, mixed 
sex, mice of TgNSE-HSP72 or C57Bl/6 were restrained and inoculated with 100 μL of 0.1% 
RML or FVB brain homogenate with a minimum of 5 mice per inoculum group.  To study the 
effect of HSP72 expression following direct exposure, mice were inoculated by intracranial 
route.  First, six to eight week old mice of mixed sex were anesthetized through inhalational 
isoflurane.  Mice were then inoculated with γ0 μL of either 0.1% RML or FVB inocula via a β9-
guage needle through the calvarium into the left parietal lobe of the cerebral cortex.  Throughout 
the course of study, mice were evaluated for clinical signs of prion disease as has been 
previously published (25) (severe ataxia, weight loss, tail rigidity, general tremors) and 
euthanized at the onset of terminal neurologic disease or at 400 days when the study was 
completed.  The distribution of mice by strain and inoculation group are summarized in Figure 
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1.1.  Following euthanasia, mice were necropsied and brains collected with clean prion-free 
instruments.  The brain was divided in half sagittally, with half being frozen at -80ºC until 
processing and the other half fixed in 10% neutral buffered formalin until sectioning and routine 
histology processing.   
 
Figure 1.1 Summary of inoculation groups and mouse strain distribution.  
The tables summarize the number of mice in each inoculation group by mouse strain and 
inoculum.   
 
Mouse tissue processing 
 Formalin fixed mouse brain halves were sectioned coronally into 2-3 mm slices to 
represent the following anatomic locations: cerebral cortex, hippocampus and thalamus, 
midbrain, cerebellum, and brainstem.  Brain sections were cassetted and submitted for routine 








Characterization of infected mice 
 All mouse brains were evaluated for PrPSc by western blot and immunohistochemistry.   
Western blotting 
 Mouse brain homogenates were evaluated for PrPSc deposition by western blotting.  
Endogenous PrPC in brain samples was digested by incubating 9 μL of 10% brain homogenate 
with proteinase K (PK) at a final concentration of 5 μg/mL at γ7ºC for 30 minutes with shaking 
followed by 45ºC for 10 minutes with shaking.  Samples were mixed with a final 1x 
concentration of reducing agent /LDS sample buffer (Invitrogen) and heated at 95ºC for 5 
minutes.  Samples were loaded on a NuPAGE 10% Bis-Tris gel (Invitrogen) and electrophoresed 
at 130 V for 2 hours.  Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane 
using a Transblot TurboTM system (Bio-Rad) following manufacturer recommendations.  The 
membrane was loaded into a pre-wetted SNAP i.d. blot holder (Millipore) then sequentially 
blocked with blocking buffer (Blocker Casein in TBS [Thermo-Scientific] and 0.1% Tween-20 
[Sigma]) for 3 minutes and probed with antibody BAR224 (Cayman Chemical) conjugated to 
horseradish-peroxidase (HRP) diluted to 0.βμg/mL in blocking buffer for 10 minutes.  Antibody 
was removed by vacuuming through the membrane using the SNAP i.d. system (Millipore) and 
the membrane was washed three times with 30 mL wash buffer (50% Blocker Casein in TBS, 
50% 1X TBS, 0.1% Tween-20) with continuous vacuum.  The membrane was developed with 
ECL-Plus Western Blotting Detection Reagents (GE) and viewed on a Luminescent Image 
Analyzer LAS-3000 (GE).   
Histology and Immunohistochemistry 
 Brain sections were stained with hematoxylin and eosin (H&E) for routine histologic 
examination and evaluated for PrPSc deposition by immunohistochemistry (IHC).  IHC was 
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performed as follows: tissues were paraffin-embedded following routine histologic processing.  
Five μm tissue sections were cut with a microtome (Leica) from paraffin embedded tissue blocks 
and placed on positively charged glass slides.  Slides were heated in an incubator prior to routine 
deparaffinization by immersion in xylene and tissue rehydration by immersion in a series of 
graded alcohols (100%, 95%, and 70%).  Slides were rinsed and then endogenous PrPC was 
digested by treatment with 1.0 μg/mL PK in 1.0mM CaCl2, 50mM Tris buffer (pH7.6) for 30 
minutes at 37ºC.  Epitopes were exposed through hydrated autoclaving heat-induced epitope 
retrieval (The RetrieverTM, Prestige Medical) in 10 mM EDTA (pH 6.0) followed by a brief 5 
minute immersion in 88% formic acid.  Sequentially, endogenous peroxide activity was blocked 
by treatment with 3.0% hydrogen peroxide in methanol and tissue sections were blocked with 
TNB blocker (Perkin-Elmer).  Slides were incubated with anti-prion primary antibody BAR224 
(Cayman Chemical) diluted to β μg/mL in blocker overnight at 4ºC.  Immunoreactivity was 
detected by incubation with Envision+TM anti-mouse secondary antibody conjugated with 
horseradish peroxidase (Dako) and visualized by incubation with AEC substrate chromogen 
(Dako).  Slides were washed with TNT buffer (1.0M Tris, 0.15M NaCl, 0.05% Tween-20 [pH 
7.5]) between each step in the above protocol.  Slides were counterstained with Mayer’s 
hematoxylin (Dako) and bluing reagent (0.1% sodium bicarbonate, 1xPBS) prior to coverslip 




HSP72 expression potentially increases cell viability in vitro following prion infection 
 Previous studies have demonstrated HSP72 production is decreased in neuroblastoma 
cells persistently infected with scrapie prions while over-expression of HSP104 in yeast can 
disaggregate and “cure” prion infection in yeast (16,26).  Therefore, we hypothesized 
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constitutive expression of HSP72 would prevent prion-associated cytotoxicity as measured by 
increased cell survival and decreased cellular pathology.  N2a cells constitutively expressing 
HSP72 (N2a-HSP72) or the empty vector (N2a-V) were exposed to either 0.1% RML prion 
mouse brain homogenate or 0.1% FVB normal mouse brain homogenate.  At 24 hours post-brain 
inoculum exposure, cell cohorts exposed to either RML or FVB normal brain homogenate 
displayed decreased cell density and an increased amount of debris in the media when compared 
to unexposed control cells (Figure 1.2A).  N2a-V cells exposed to RML often displayed 
decreased cell density, however, the degree of this effect often varied between experiments.  By 
72 hours post-exposure, unexposed N2a-HSP72 and N2a-V control cells had reached 90-100% 
confluency and all cell cohorts were passaged and counted.  Visually, cells exposed to brain 
homogenate, either RML or FVB, appeared to have less cell density, with N2a-V cells exposed 
to RML displaying the least cell density (Figure 1.2B).  Cell counts at 72 hours post-exposure 
confirmed the cell growth patterns observed with unexposed control cells displaying the greatest 
growth and N2a-V cells exposed to RML displaying the least growth (Table 1.1).  No differences 
between N2a-HSP72 and N2a-V cell counts were observed and only minimal differences in cell 
density was observed between N2a-HSP72 cells exposed to FVB or RML brain homogenate.  
These results suggest HSP72 expression protected N2a cells against the insult of prion brain 




Figure 1.2 Microscopic evaluation of cells 24 and 72 hours following prion exposure. 
A. Cell images 24 hours following prion exposure.  Comparable cell densities are observed 
between unexposed cells, cells exposed to FVB brain homogenate, and N2a-HSP72 cells 
exposed to RML.  N2a-V cells exposed to RML had the least cell density.  All images 10x 
magnification.   
B. Cell images 72 hours following prion exposure.  Unexposed control cells are 90-100% 
confluent.  Decreased cell density was observed in all cells exposed to brain homogenate 
inoculum.  Cell density appeared equivalent between cells exposed to control FVB brain 
homogenate and N2a-HSP72 cells exposed to RML.  N2a-V cells exposed to RML had the 





Table 1.1 Cell counts 72 hours post-exposure.   
Similar to Figure 1.2, treatment with either RML or FVB brain homogenate caused a decrease in 
cell viability when compared with unexposed controls.  N2a-HSP72 cells exposed to RML 
display similar cell counts as cells exposed to FVB brain homogenate, however, N2a-V cells 
exposed to RML displayed the least cell viability.  Data represents average cell counts from 3 
experiments.   
   Uninfected 0.1% FVB 0.1% RML 
N2a-HSP72 1.59 x 106 0.63 x 106 0.66 x 106 
N2a-V 1.64 x 106 0.50 x 106 0.31 x 106 
 
RT-QuIC of prion-exposed cell lysates 
 We predicted HSP72 expression would prevent prion protein conversion; thus, we 
expected N2a-HSP72 cells to produce less PrPSc than N2a-V following RML infection.  We 
compared the amount of PrPSc in cell lysates collected over 6 passages by RT-QuIC amyloid 
formation kinetics.  First, we demonstrated mouse-origin RML prions could convert SHrPrP 
substrate into amyloid and be detected by RT-QuIC (Figure 1.3).  We seeded the RT-QuIC 
reaction with a dilutional series of RML infected mouse brain homogenate from 10-4 to -9 and 
a corresponding dilutional series of FVB negative brain homogenate and were able to 
specifically detect RML prion-seeded amyloid formation from 10-4 to 10-6 dilutions.  No 





Figure 1.3 Representative RT-QuIC fluorescence curves of RML dilutional series.  
A dilutional series of RML brain homogenate and FVB brain homogenate demonstrate mouse-
origin RML prions successfully seed the RT-QuIC reaction using SHrPrP substrate.  The 
detection range extended from 10-4 to 10-6 dilution and intermittent detection was observed 
after 10-7.  No spontaneous amyloid formation was observed in reactions seeded with FVB 
brain homogenate.   
 
Next, we analyzed cell lysates collected from the immediate post-infection time period 
for RT-QuIC prion-templated amyloid formation to ensure our protocol was capable of 
generating cell infection and our N2a clones were susceptible to infection.  At 1 hour post-
exposure, no prion-seeded amyloid formation was detected in cell lysates (Figure 1.4B).  At 24 
hours post-exposure, robust RT-QuIC amyloid formation, at levels comparable to the inoculum, 
was observed in cells exposed to RML indicating our N2a cells were capable of de novo prion 
conversion (Figure 1.4B).  Although RT-QuIC detected prion-seeded amyloid formation in cells 
exposed to RML at 72 hours post-exposure, the time to detectable amyloid formation was 
slower, suggestive of a decreased prion burden when compared with the 24 hour collection.  
Overall, these findings show our N2a-HSP72 and N2a-V cells are susceptible to RML prion 




Figure 1.4 RT-QuIC of early cell culture infection. 
A. RT-QuIC of cell infection inoculum.  RT-QuIC detected RML at the 0.1% concentration 
used to inoculate N2a cells.   
B. RT-QuIC of cell lysates 1 hour to 72 hours post-brain homogenate exposure.  No prion-
seeded RT-QuIC amplification was detected 1 hour post-exposure.  Prion-seeded RT-QuIC 
amplification was detected in N2a-V and N2a-HSP72 cells harvested 24 hours after exposure 
to RML brain homogenate.  No spontaneous amyloid conversion was detected in cells exposed 
to FVB brain homogenate or unexposed controls (N2a-V C and N2a-HSP72 C).  At 72 hours 
post-exposure, RT-QuIC prion seeding was still restricted to cells exposed to RML inoculum, 
however, the time to positive was delayed by approximately 10 hours compared with the 24 
hour collection.  No spontaneous amyloid formation was detected in cells exposed to FVB 
inoculum or unexposed controls.  
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 HSP72 functions by correcting aberrant protein folding and preventing aggregation.  
Therefore, we predicted cells that constitutively expressed HSP72 would produce less PrPSc and 
eliminate prion infection at an earlier passage when compared with control N2a-V cells.  To 
analyze the PrPSc burden over time, we evaluated the level of prion production in cells following 
prion infection over 6 passages by RT-QuIC rate analysis.  Previous studies have established the 
RT-QuIC amyloid formation rate directly correlates with the prion concentration in the sample 
seeding the reaction (20,21). At passage 1, RT-QuIC prion-seeded amyloid formation was 
limited to N2a-HSP72 and N2a-V cells exposed to RML, consistent with prion infection (Figure 
1.5).  Over the 6 passages, the rates of amyloid formation remained equivalent between N2a-
HSP72 and N2a-V RML-infected cells (p>0.05, Mann-Whitney non-parametric test).  We also 
observed that the rate of amyloid formation in these cells steadily decreased between subsequent 
passages indicating the amount of PrPSc was decreasing over time.  We concluded HSP72 






Figure 1.5 RT-QuIC comparison of prion levels over time  
Prion-templated amyloid formation was detected in NSE-HSP72 and N2a-V cells exposed to 
RML in passages 1 through 6.  There was no significant difference between the average rates of 
amyloid formation between the two cell types.  The average rates of amyloid formation were 
observed to decrease as passages progressed consistent with a decrease in prion burden in the 
samples.  Minimal, insignificant, amyloid formation of one to two replicates was observed in 
control cell samples due to spontaneous conversion of SHrPrP substrate.   
 
HSP72 expression does not alter prion disease course 
 We hypothesized HSP72 would protect against prion-associated disease, therefore, we 
compared the survival times between NSE-HSP72 and C57Bl/6 mice inoculated with RML.  
Both mouse strains developed clinical signs associated with prion infection following RML 
intraperitoneal (IP) inoculation.  No significant difference was observed in survival time between 
the NSE-HSP72 and C57Bl/6 mouse strains, with median survival times of 227 days and 224 
days, respectively (Fig 1.6A).  Negative control FVB IP inoculated mice from either genetic 
background did not develop clinical disease and lived for the entire study length, 400 dpi.  This 
demonstrates HSP72 neuronal overexpression does not protect against peripheral, IP, RML 
exposure.  Interestingly, RML intracranial (IC) inoculated NSE-HSP72 displayed a slightly 
shorter survival time with a median of 165 dpi when compared to RML IC inoculated C57Bl/6 
mice with a median survival of 175 dpi (p=0.0265, log-rank test) (Fig 1.6B).  In summary, these 
data demonstrate neuronal expression of HSP72 does not enhance survival from RML-prion 
disease.  Although the difference between the IC NSE-HSP72 and C57Bl/6 inoculation groups is 
statistically significant, a larger study is necessary to evaluate if HSP72 expression biologically 




Figure 1.6 Survival curve following RML prion inoculation 
A. Intraperitoneal inoculation survival curve.  NSE-HSP72 mice and C57Bl/6 mice IP noculated 
with RML and euthanized due to terminal disease displayed no significant differences between 
the disease time course.  Control mice inoculated with FVB brain homogenate did not display 
clinical disease and survived throughout the course of the study.   
B.  Intracranial inoculation survival curve.  NSE-HSP72 mice and C57Bl/6 mice IC inoculated 
with RML were euthanized due to terminal disease, however, NSE-HSP72 mice had a shorter 
disease course by approximately 2 weeks (*, p<0.05).  Control mice inoculated with FVB mouse 
brain homogenate did not display clinical disease and survived throughout the course of the 
study.   
 
HSP72 expression does not alter PrPSc production or neuropathology 
 The amount of PrPSc formed during disease between RML-inoculated NSE-HSP72 and 
C57Bl/6 mice was compared by western blotting.  All animals from both IP and IC inoculation 
routes that displayed clinical signs and were euthanized for prion disease had demonstrable PrPSc 
in brain homogenates and at comparable densities (Figure 1.7).  There was no apparent 
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difference in the level of PrPSc brain accumulation between NSE-HSP72 and C57Bl/6 mice or by 
inoculation routes.  No animals inoculated with FVB brain homogenate displayed PrPSc in 
homogenates.   
 
 
Figure 1.7 Representative western blot of PrPSc in brain homogenates from mice inoculated 
with RML or FVB brain homogenate.   
A. Intraperitoneal inoculation. PrPSc was detected in brain homogenates from C57Bl/6 and NSE-
HSP72 mice inoculated with RML following PK digestion but was not observed in FVB 
inoculated mice.  No difference was observed in the banding pattern or relative density of PrPSc
in the brain homogenates.   
B. Intracranial inoculation.  Similar to the IP inoculation in A, PrPSc was detected in brain 
homogenates from C57Bl/6 and NSE-HSP72 mice inoculated with RML following PK digestion.  
No difference was observed in the density or banding pattern.  No PK resistant material was 




To evaluate if HSP72 expression alters RML prion pathology, brain sections from RML-
inoculated and FVB-control animals were examined by H&E staining and IHC.  Both NSE-
HSP72 and C57Bl/6 mice with inoculated with RML, either by IP or IC routes, and euthanized 
for terminal disease displayed similar pathology consistent with published RML lesion profiles 
(25).  H&E evaluation of brain tissue displayed white matter vacuolation (spongiosis) of the 
cerebral cortex, cerebellum, and brainstem (Figure 1.8A).  No difference in the degree of 
spongiosis was observed between animal types or inoculation routes.  IHC evaluation displayed 
PrPSc immunoreactivity in the hippocampus, thalamus, cerebellum and brainstem, consistent 
with RML prion infection (Figure 1.8B).  No difference in lesion distribution or severity was 
detected between NSE-HSP72 and C57Bl/6 mice or by inoculation route.  Control mice 
inoculated with FVB did not display any PrPSc immunoreactivity in their brains.  In summary, 
HSP72 expression in neurons did not alter lesion development or PrPSc accumulation in brains 




Figure 1.8 Microscopic comparison of brain lesions in NSE-HSP72 and C57Bl/6 mice 
inoculated with RML.  
A. H&E evaluation of brain lesions.  NSE-HSP72 and C57Bl/6 mice inoculated with RML 
displayed white matter spongiosis in the cerebral cortex and cerebellum consistent with prion 
infection.  Mice inoculated with FVB normal brain homogenate did not display any lesions.   
B. IHC evaluation of PrPSc brain accumulation.  PrPSc immunoreactivity, characterized by 
diffuse and small punctate deposits in the hippocampus, thalamus, cerebellum, and brainstem, 
was detected equally in NSE-HSP72 and C57Bl/6 mice inoculated with RML.  Brain sections 





 Heat-shock protein 72 expression has been shown to protect against the toxic effects of 
protein misfolding in in vitro and in vivo models of neurodegenerative diseases (3).  This 
protection was illustrated by a decrease in the amount of aberrant protein produced and increased 
cell viability (3).  In contrast to these studies, we did not observe a protective effect in cell 
culture or mouse investigations of HSP72 expression of RML prion infection.  Potential reasons 
for the differences between our results and other models of protein misfolding diseases include 
variations in HSP72 expression in the mouse models used for experiments and separate 
subcellular locations of HSP72 and the prion protein.   
 The majority of in vivo studies examining the influence of HSP72 on neurodegenerative 
diseases used a transgenic C57Bl6 mouse with HSP7β expression controlled by the -actin 
promoter yielding HSP72 expression in all cell types (9,10,27).  In contrast, our study focused on 
HSP72 expression in neurons by using transgenic mice with the gene construct under control of 
the neuron specific enolase promotor (23).  By extending expression to other cell types, HSP72 
may be initiating additional cell-mediated mechanisms of protection, such as microglial 
activation, that synergistically act to decrease protein aggregation (28).  Additionally, as would 
be expected by expressing HSP72 in all cell types, the total amount of HSP72 produced is 
greater than when expression is restricted to neurons (23).  Potentially, this increased dose of 
HSP72 is needed to abrogate aberrant protein aggregation and the amount of HSP72 in our 
mouse strain is below the therapeutic threshold.  Further study is needed to investigate if HSP72 
expression in additional cell types besides neurons is beneficial in prion pathogenesis.   
 A second potential cause of our negative mouse data is the separate cellular locations of 
HSP72 expression and pathogenic prions.  HSP72 typically resides in the cytoplasm whereas 
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PrPC is anchored in lipid rafts on the outer cell membrane (2,29,30).  PrPSc has been shown to 
form on the cell surface and traffic through cells within the endosome-lysosome system (31).  
Despite the appearance of spatial segregation, during the stress response HSP72 has been shown 
to translocate to lipid rafts during the stress response and be released into the extracellular 
environment, both locations where it could encounter PrPSc (32).  HSP72 has also been shown to 
be protective in mouse models of AD, another protein-misfolding disease where the nascent 
protein is located in the membrane and the aggregated amyloid- is extracellular (10).  This 
suggests HSP72 and prions should come in contact, however, it is unknown how limiting the 
expression of HSP72 to neurons affects the production and function of extracellular HSP72 in 
our transgenic mouse model. 
 Our in vitro cell culture studies provided mixed results with HSP72 expression.  
Observing the cell density and cell counts over 3 days post-inoculation suggested HSP72 
expression protected against RML-associated prion toxicity.  However, analysis of the RML 
burden over 6 passages following infection did not demonstrate any differences in prion 
production between cells expressing HSP72 or not.  Analysis of the RT-QuIC amyloid formation 
rates immediately following prion exposure and throughout passaging demonstrated the prion 
concentration was gradually decreasing indicating our transfected N2a cells were able to be 
infected but did not efficiently propagate infection between passages.  This problem has 
previously been recognized in prion infection cell culture, where N2a clones display variable 
permissiveness or resistance to scrapie prion infection and a GAG-protein construct was 
necessary to maintain prion propagation in RKE cells between passages (33,34).  Another 
potential complication is the stringent passage conditions we performed, in which we potentially 
diluted infected cells faster than prions propagate.  Some prion cell panel assays do not perform 
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any passage steps after infection or only do minimal cell splitting when passaging which 
suggests overall cellular prion replication occurs at a slow rate (unpublished data, Glenn 
Telling).  Potential alternative experimental approaches to analyze HSP72 expression in vitr  
include identifying the most prion-susceptible N2a subclones from our vector transfected cells or 
terminally differentiating our N2a-cells into neurons prior to infection.   
 In summary, we investigated the potential for HSP72 to mitigate prion pathogenesis in 
cell culture and mouse models of murine-adapted scrapie.  In contrast to its protective effect in 
models of other protein misfolding diseases, HSP72 expression in neurons did not alter the 
disease course or prion accumulation following infection.  Further investigation is needed to 
know if HSP72 expression can provide protection in prion diseases when expressed in additional 
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Natural exposure of deer to the misfolded infectious prion (PrPCWD) in chronic wasting 
disease (CWD) is believed to occur through environmental exposure by aerosol or oral routes.  
Studies in white-tailed deer mimicking these exposure routes with (in retrospect) relatively large 
challenge doses detected PrPCWD in the retropharyngeal lymph node at 1.5 months and tonsil at 3 
months by western blotting and immunohistochemistry.  However, the full extent of PrPCWD 
distribution prior to these time points and the chronological progression of disease during early 
infection remains unknown.  To address this knowledge gap in pathogenesis, we challenged 
white-tailed deer with CWD prions by intravenous or mucosal exposure routes (oral and oro-
nasal) and performed necropsies at 1 and 3 days and 1, 2, 3, and 4 months to assess the tissue 
distribution of PrPCWD. To enhance PrPCWD detection at early post-infection time points, tissues 
were assayed using several amplification techniques: real-time quaking induced conversion assay 
(RT-QuIC) and tyramide signal amplification immunohistochemistry (TSA-IHC).  Although we 
were unable to detect PrPCWD in the immediate period following mucosal exposure, we detected 
PrPCWD seeding activity in vascular organs 15 minutes and 72 hours post-IV exposure.   In an 
extended survey following mucosal exposure, PrPCWD was first detected in the oropharyngeal-
associated lymph nodes at 1 month post-exposure (MPE).  Expanding PrPCWD replication was 
detected at 2 MPE in oropharyngeal lymph nodes and by 3 MPE, PrPCWD had spread to all 
systemic lymphoid tissues.  At 4 MPE, PrPCWD detection remained confined to lymphoid tissues 
and was not yet evident in central nervous system tissues.  These results indicate that the earliest 
trans-mucosal entry by CWD prions is in the upper alimentary tract and replication in the 
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lymphoid tissues draining the oropharyngeal cavity followed by rapid dissemination to systemic 
lymphoid tissues prior to neuroinvasion.  
 
Background 
 Chronic wasting disease (CWD) is a naturally occurring TSE of cervids, including deer, 
elk, and moose (1).  CWD was first recognized in Colorado in 1967 and has since spread to 
captive and free-ranging cervid populations in 24 states and three additional countries, Canada, 
the Republic of Korea, and Norway (2,3).  Clinical signs include progressive wasting despite 
polyphagia, bruxism, head tremors, and ataxia (1,4).  Like other transmissible spongiform 
encephalopathies, clinical disease is associated with spongiform change and accumulation of the 
infectious prion isoform, PrPCWD, in the central nervous system, most consistently observed 
affecting the nucleus of the vagus nerve in the obex region of the medulla oblongata (5-7).   
Natural horizontal CWD transmission is predicted to occur through direct contact with 
infected animals or by indirect environmental exposure associated with foraging activities (8).  
Infectious CWD prions have been demonstrated in body fluids and excreta, including saliva, 
urine, feces, contaminated fomites, and pasture (8-12).  Once CWD has contaminated the 
environment it has been shown to persist and remain infectious for years, potentially through 
complexing with soil (13).  Vertical transmission has also been described, however, it is unclear 
what degree it plays in the spread of CWD (14).   
 Like other TSEs, the pathogenesis of CWD is influenced by the PRNP gene sequence and 
four polymorphisms have been identified in white-tailed deer: Q95H, G96S, A116G, and Q226K 
(15).  Of the identified polymorphisms, 95Q, 96G, and 116A, are more commonly represented in 
the deer population and reported with higher frequency in field-cases of CWD (16).  Research 
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has demonstrated at least one copy of the 96S allelic variation prolongs the CWD incubation 
period in deer, up to 230%, and potentially impedes PrPCWD conversion (2,17,18).   
 Evidence suggests CWD pathogenesis has many similarities to scrapie, including a 
lymphoid replication phase prior to neuroinvasion (19).  A survey of mule deer from CWD 
endemic areas identified PrPCWD in tonsil biopsies without overt clinical signs of disease (20).  
Experimental studies of CWD transmission following relatively large oral challenge with CWD+ 
brain homogenate, have demonstrated PrPCWD in gastrointestinal-associated lymphoid tissues as 
early as 42 days (21) and spread to systemic lymphoid tissues by 90 days post-exposure (22).  
However, there remains relatively little information regarding the chronological progression of 
PrPCWD in deer tissues during the early post-exposure period. 
To reveal features of the early CWD pathogenesis, we examined the distribution and 
accumulation of PrPCWD after oral and intravenous exposure in white-tailed deer using both 
traditional and modern amplification methods. Prions rapidly disseminated to highly 
vascularized organs within 15 minutes and remained within these tissues at 3 days post-exposure.  
Following mucosal exposure, we found the earliest evidence of trans-mucosal prion entry in the 
upper alimentary tract in the lymphoid tissues draining the oropharyngeal cavity, followed by 
rapid dissemination to systemic lymphoid tissues prior to neuroinvasion.  This study highlights 
the contribution of the lymphoid system in early CWD pathogenesis following mucosal 
exposure.   
 
Methods 
Animal care and study design 
 Indoor housed, hand-raised white-tailed deer (WTD) (Odocoileus virginianus) were 
provided through long collaboration with Sally Dahmes and David Osborn.  WTD were 
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maintained in strict accordance with Colorado State University Animal Care and Use 
Committee.  PrPC genotype sequence at codon 96 was determined as previously described 
(14,23,24).   
Intravenous-inoculation:  
 Four WTD were intravenously inoculated with 0.55 grams of CWD-positive (CWD+) 
brain homogenate.  One WTD was inoculated with CWD-negative (CWD-) brain homogenate 
following similar route as a negative control.  The brain inocula were prepared in sterile 1xPBS 
containing 2.0% penicillin-streptomycin (Life Technologies).  WTD were inoculated into the 
jugular vein over a period of 5 minutes while under sedation.  Two CWD+ deer were sacrificed 
15 minutes post-inoculation and the remaining 2 CWD+ and 1 CWD- animals were collected 72 
hours post-inoculation.  No signs of clinical disease were detected throughout the course of 
study. 
Mucosal-inoculation:  
WTD identified by 900-series were inoculated with a combined oro-nasal inoculation of 
homogenate consisting of 0.55 grams pooled cervid brain that was confirmed CWD positive by 
western blot.  Oral inoculation was performed by instilling 0.5g of brain directly into the 
animal’s mouth using a syringe.  Aerosol inoculation was performed by atomizing brain 
homogenate corresponding to 0.05 g of brain using a NasonexTM-style sprayer directly in the 
nostrils.  Negative control WTD were inoculated with a similar dose and route of pooled CWD-
negative cervid brain homogenate.  WTD were sacrificed at either 24 hours or 72 hours post-
inoculation.  WTD identified by 1100 or 1200-series were inoculated with either 0.5 grams of 
CWD positive or CWD negative brain homogenate and sacrificed at 1, 2, 3, or 4 months post-
inoculation.  PRNP genotype at codon 96 was evenly distributed throughout the collection time-
55 
 
points to ensure equal genetic representation (Figure 2.1).  No signs of clinical disease were 
detected throughout the course of study. 
 
Figure 2.1 Overview of WTD PRNP genotype distribution of mucosal-exposure cohort.  
White tailed deer were collected at 1 and 3 days or 1, 2, 3, and 4 months.  PRNP codon 96 




 Complete necropsy and tissue collection of each WTD was performed at time of 
sacrifice.  Lymphoid tissues, obex, ileum and vomeronasal organ (VNO) were analyzed for 
PrPCWD amyloid seeding activity by RT-QuIC and PrPCWD immunoreactivity by IHC.  Many 
other tissues were collected from deer at necropsy but were not analyzed for the present report.  
Each tissue was collected with an individual, clean, prion-free instrument to avoid cross-
contamination.  Tissues were split into two with half frozen and stored at -80 C until use.  The 
other half of tissue was fixed in periodate-lysine-paraformaldehyde (PLP) for 4 days before 
changing to sterile 1xPBS until trimming and histology tissue cassetting, followed by 70% 
ethanol for long-term storage.  Tissue cassettes were processed into paraffin-embedded blocks 
following routine histologic techniques.  Frozen tissues were processed into ten percent weight-
per-volume tissue homogenates using 1xPBS (Life Technologies) and a Bullet BlenderTM tissue 




 PrPCWD was detected following a two-step immunostaining procedure with tyramide-
signal (TSA) enhancement as previously described with minor modifications (25).  Briefly, 5 μm 
tissue sections were mounted on positively charged glass slides.  Following routine 
deparaffinization with xylene and rehydration with graded alcohols, tissues were subjected to 1 
μg/mL proteinase K digestion at γ7 C to remove native PrPC.  Epitope exposure was performed 
using hydrated autoclaving antigen retrieval in 10 mM EDTA, pH 6.0.  Tissues were briefly 
exposed to 88% formic acid prior to quenching endogenous peroxide activity with 3.0% 
hydrogen peroxide in methanol.  Tissue sections were blocked with proprietary protein block, 
TNB (Perkin-Elmer), followed by sequential application of primary anti-prion protein antibody 
BAR224 (Cayman chemical) at 0.5μg/mL, a 1:β000 dilution and secondary anti-mouse antibody 
conjugated to horseradish peroxidase (HRP) (Envision+TM, Dako).  Antibody signal was 
enhanced with Tyramide Signal AmplificationTM (Perkin Elmer) following the suggested 
protocol.  Immunoreactivity was detected using AEC substrate-chromogen (Dako).  Coverslips 
were mounted using aqueous mounting media and staining visualized by light microscopy.   
RT-QuIC protein purification 
 RT-QuIC experiments were performed with recombinant truncated Syrian hamster PrPC 
(SHrPrP) encoding residues 90-231, which was expressed and purified as previously described 
(26,27).  Briefly, SHrPrP was expressed in BL21 Rosetta Escherichia coli (Novagen). Bacteria 
were cultured at 37°C in lysogeny broth (LB) media in the presence of selection antibiotics 
kanamycin and chloramphenicol until the final OD600 was at least 2.5.  Cell lysis was performed 
using BugbusterTM reagent supplemented with LysonaseTM (EMD Biosciences) and inclusion 
bodies harvested by centrifugation at 15,000 x g.  The inclusion body pellet was solubilized (8M 
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guanidine hydrochloride, 100mM Na2PO4) prior to application to NiNTA superflow resin 
(Qiagen) that had been previously equilibrated with denaturation buffer (6M guanidine 
hydrochloride, 100 mM Na2PO4, 10mM Tris).  The resin-SHrPrP was applied to a XK16-60 
column (GE Healthcare) and purified using a Bio-Rad DuoflowTM FPLC using a gradient from 
denaturation buffer to refolding buffer (100mM Na2HPO4, 10mM Tris) to induce protein 
refolding.  Refolding was followed by a gradient from refolding to elution buffer (100mM 
NaH2PO4, 10mM Tris, 0.5 M imidazole) with all fractions being collected.  Fractions from the 
elution peak were combined and dialyzed against 4L of buffer (20mM NaH2PO4) overnight.  
Final protein concentration was determined using the A280 and a coefficient of extinction of 
β5,900 in Beer’s Law.     
RT-QuIC assay 
Lymphoid and parenchymal tissues 
 Tissue homogenates were treated to sodium phosphotungstic acid (NaPTA) precipitation 
to enhance detection by RT-QuIC.  Briefly, 100 μL of a 1% tissue homogenate solution was 
incubated and shaken with 7 μL NaPTA solution (0.5g sodium phosphotungstic acid,  
0.43g MgCl2-6-hydrate, pH 4.0) for 1 hour at 37° C and 1400 rpm.  The solution was pelleted by 
centrifugation at 21,130 rcf for 30 minutes.  The supernatant was removed and remaining pellets 
were resuspended in RT-QuIC dilution buffer (0.1% SDS/1xPBS) corresponding to the original 
volume of homogenate to maintain consistent protein concentration.  Two μL of resuspended 
NaPTA precipitated tissue sample was used to seed each RT-QuIC reaction.   
Nervous tissues 
 Nervous tissues were alcohol precipitated prior to RT-QuIC assay.  Ten μL of a 10% 
tissue homogenate was incubated at room temperature with 100% ethanol for 5 minutes.  
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Proteins were pelleted by centrifugation at 21,130 rcf for 5 minutes and the supernatant 
discarded.  The procedure was repeated and the final protein pellet was resuspended in 10 μL of 
RT-QuIC dilution buffer.  Two μL of a 10-1 dilution of the precipitated nervous tissue proteins 
were used to seed the RT-QuIC reaction.   
Assay conditions 
RT-QuIC was performed as previously described (26,27).  Briefly, RT-QuIC experiments 
were carried out in black, optical bottom 96-well plates (Nunc) with each well containing 0.1 
mg/mL SHrPrP substrate and RT-QuIC reaction buffer (20mM NaH2PO4, 320mM NaCl, 1.0mM 
EDTA, 1mM Thioflavin T).  RT-QuIC experiments were carried out in a BMG Labtech 
PolarstarTM fluorometer with each cycle consisting of 1 minute shaking at 700 rpm followed by 1 
minute rest, repeated for 15 minutes.  Fluorescence readings with an excitation of 450 nm, 
emission of 480 nm, and gain of 1700 were taken at the completion of each 15 minute shake/rest 
cycle by measuring each well 20 flashes and an orbital average of 4.  Each RT-QuIC experiment 
consisted of 250 fluorescence readings, a total of 62.5 hours.   
RT-QuIC data analysis 
 Data for each sample was collected by three separate RT-QuIC experiments with 4 
replicates each for a total of 12 replicates.  Individual replicates were considered to have positive 
amyloid formation if their fluorescence rose above a pre-determined threshold set at 5 standard 
deviations above the average of the baseline fluorescence.  RT-QuIC rates of amyloid formation 
were calculated as previously described (26,28).  Rates of amyloid formation were normalized to 
the plate positive control minimize any individual experiment variation by dividing each sample 
rate of amyloid formation by the fastest positive control rate of amyloid formation.  Sample data 
was statistically evaluated using GraphPad software.  RT-QuIC replicate distributions were 
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determined to be normally distributed using D’Agostino test for normality and a p-value <0.05.  
The rates of amyloid formation from tissue homogenates from PrPCWD exposed animals were 
compared to corresponding negative controls by one sample t-test and considered positive if the 
p-value <0.05.   
 
Results 
PrPCWD amplifies in lymphoid tissues during the early course of infection 
24 and 72 hours post-mucosal exposure.  In WTD collected at 24 and 72 hours post-mucosal 
CWD exposure, occasional RT-QuIC sample replicates of the prescapular, mandibular, and 
hepatogastric lymph nodes displayed amyloid seeding activity, however, the average rates of 
amyloid seeding for these samples were not significantly different than corresponding negative 
control tissues (Figure 2.2).  IHC analysis of tissues from these early time points did not display 





Figure 2.2 24 and 72 hours post-mucosal exposure.   
A. RT-QuIC of tissues collected 24 hours post-mucosal exposure.  Rare tissues, such as the 
prescapular LN, mandibular LN and RAMALT, displayed minor rPrPC amyloid conversion, 
however rates of amyloid formation were not statistically different than corresponding negative 
control tissues.  Data displayed is mean and standard error of mean (SEM) from 8 replicates 
representing 2 separate experiments.  (LN= lymph node; Retro LN = Retropharyngeal lymph 
node; RAMALT= rectoanal mucosal associated lymphoid tissue; VNO= vomeronasal organ) 
B. RT-QuIC of tissues collected 72 hours post-mucosal exposure. Rare tissues, such as the 
prescapular LN and spleen, displayed minor rPrPC amyloid conversion, however rates of amyloid 
formation were not statistically different than corresponding negative control tissues (p>0.05, 
one-sample t-test).  Data displayed is mean and SEM from 8 replicates representing 2 separate 
experiments.   
C. RT-QuIC of negative control tissues collected at 72 hours post-mucosal exposure.  Rare 
tissues displayed minor elevated rates consistent with spontaneous amyloid formation of SHrPrP 
substrate.  Data displayed is mean and SEM from a minimum of 8 replicates and 2 separate 





15 minutes and 72 hours post-intravenous exposure. To contrast PrPCWD tissue distribution with 
mucosal exposure, deer were inoculated IV with CWD+ or CWD- brain homogenate and 
collected 15 minutes or 72 hours post-inoculation.  We observed variable amyloid seeding in 
highly vascularized organs at both 15 minutes and 72 hours post-exposure, including the lung 
and liver (Figure 2.3).  No PrPCWD immunoreactivity was observed on TSA-IHC examination of 
the corresponding tissues.   
 
Figure 2.3 15 minutes and 72 hours post-IV inoculation.  
A. PrPCWD detection 15 minutes post-IV inoculation.  PrPCWD amyloid seeding was variably 
detected in the lung, kidney, liver, and right ventricle of the heart 15 minutes following IV 
inoculation.  Of those tested, the right caudal lung, left caudal lung, and right ventricle samples 
from animal 964 had amyloid formation rates significantly different than the corresponding 
negative control (*, p<0.05, Wilcoxon signed rank test).  Data represents mean and SEM of 8 
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replicates and 2 separate experiments.   
B. PrPCWD detection 72 hours post-IV inoculation.  Variable PrPCWD amyloid seeding was 
detected in all lung lobes, liver, and right atrium.  The samples from deer 956 that displayed 
significant rates of amyloid formation included: the right atrium of the heart, and the right and 
left caudal lung lobes (**, p<0.01, Wilcoxon signed rank test).  From deer 1030, only the liver 
sample displayed significant rate of amyloid seeding (*, p<0.05, Wilcoxon signed rank test).  
Data represents mean and SEM of 8 replicates and 2 separate experiments.   
C. No PrPCWD amyloid seeding detected in the negative control deer.   
 
One month post exposure (MPE).  At 1 MPE, significant PrPCWD amyloid seeding activity 
(p<0.01, one sample t-test) was detected in the retropharyngeal lymph nodes from two 96G 
WTD and the parotid lymph node from one 96G WTD when compared to corresponding 
negative controls (Figure 2.4A).  By comparison, no significant amyloid seeding was observed in 
tissues from 96S WTD at 1 MPE.  This indicates the amyloid seeding detected in 96G tissues is 
consistent with de novo prion generation in these tissues and not residual inoculum.   
TSA-IHC evaluation of lymphoid tissues at 1 MPE demonstrated faint granular PrPCWD 
immunoreactivity in rare germinal centers of tonsils in two of the three 96G WTD (Figure 2.4B).  
Similar faint granular PrPCWD immunoreactivity was detected in the parotid lymph node with 
corresponding amyloid seeding detected by RT-QuIC.  Despite significant RT-QuIC amyloid 
seeding, TSA-IHC failed to demonstrate PrPCWD immunoreactivity in retropharyngeal lymph 
nodes.  The variation in PrPCWD tissue detection at this early disease time point is likely due to 
unequal tissue distribution and sectioning differences.  No PrPCWD immunoreactivity was 





Figure 2.4. 1 MPE collection.  
A. RT-QuIC of 96G, 96S, and negative control tissues collected at 1 MPE.  Three tissues 
displayed significant RT-QuIC amyloid seeding: 1219 retropharyngeal lymph node, 1202 
retropharyngeal lymph node, and 1219 parotid lymph node (one sample t-test, p<0.05).  No 
significant PrPCWD amyloid seeding formation was observed in 96S WTD tissues.  Data 
represents mean rate of amyloid formation and standard error of mean (SEM) of 12 replicates 
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from 3 separate experiments.   
B. Representative TSA-IHC from 96G WTD collected at 1 MPE.  Minimal to no PrPCWD 
immunoreactivity was detected in tonsils from WTD at 1 MPE.  All images 200x magnification; 
scale bar = 50μm. 
 
Two MPE.  At 2 MPE, significant PrPCWD seeding activity (p<0.01, one sample t-test) was 
consistently detected in lymph nodes draining the head and neck including the tonsil, 
retropharyngeal lymph node, and mandibular lymph node (Figure 2.5A).  In addition, one 96G 
WTD had significant seeding activity in the parotid lymph node. Compared to 1 MPE (Figure 
2.4A), the tonsil and retropharyngeal lymph node at 2 MPE displayed a faster amyloid formation 
rate, consistent with greater accumulation of PrPCWD in these tissues.  As at 1 MPE, lymphoid 
tissues from 96S WTD at 2 MPE contained no detectable PrPCWD amyloid seeding activity.   
TSA-IHC evaluation of lymphoid tissues from 96G WTD revealed PrPCWD 
immunoreactivity in tonsils with greater distribution of staining when compared with 1 MPE 
tissues (Figure 2.5B)(summarized in Table 1).  In addition, PrPCWD immunoreactivity was 
observed in retropharyngeal lymph nodes from two 96G WTD.  No PrPCWD immunoreactivity 





Figure 2.5 2 MPE collection.  
A. RT-QuIC of 96G WTD, 96S WTD, and negative control tissues collected at 2 MPE.  PrPCWD 
amyloid seeding was detected in oropharyngeal lymphoid tissues from at least 1 96G WTD 
collected at 2 MPE, including the tonsil, retropharyngeal, mandibular, and parotid lymph nodes 
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(one sample t-test, p<0.01). Amyloid formation rates from 96S WTD tissues were not 
significantly different than the negative control.  Data represents mean and SEM of 12 replicates 
from 3 separate experiments.  
B. Representative TSA-IHC from 96G WTD collection at 2 MPE.  Mild PrPCWD 
immunoreactivity was detected in a small number of germinal center lymphoid follicles in tonsil 
and retropharyngeal lymph nodes.  Images are β00x magnification; scale bar = 50 μm. 
 
Three MPE. Following 3 MPE, significant PrPCWD seeding activity expanded from lymph nodes 
associated with the head and neck detected at earlier collection times to include all systemic 
lymphoid tissues examined (Figure 2.6A) from at least one of the two 96G WTD.  The lymphoid 
tissues draining the head and neck had the highest rates of amyloid seeding activity consistent 
with a greater PrPCWD burden.  The PrPCWD seeding activity in spleen is consistent with systemic 
spread of prions, either through lymphoid cell trafficking or blood. 
 TSA-IHC analysis of tissues at 3MPE collection identified PrPCWD immunoreactivity in 
the majority of systemic lymphoid tissues in addition to oropharyngeal lymphoid tissues (Figure 
2.6B) (summarized in Table 2.1).  Lymph nodes draining the head and neck had the greatest 





Figure 2.6 3 MPE collection.  
A. RT-QuIC of 96G WTD tissues collected at 3 MPE.  The majority of tissues display positive 
rates of amyloid formation that are statistically different than the corresponding negative control 
tissues (one sample t-test, p<0.05).  The two tissues that are not significant are: 1207 mesenteric 
lymph node and 1207 parotid lymph node.  The increase in lymphoid tissue distribution at 3 
MPE is consistent with systemic prion spread.  Amyloid formation rates in the oropharyngeal 
lymphoid tissues are higher at 3 MPE when compared with 2 MPE (Figure 2.5A) consistent with 
an accumulation of PrPCWD with the longer incubation time.  Data represents mean and SEM of 
12 replicates from 3 separate experiments.  3 MPE tissues were compared with 4 MPI negative 
control tissues for statistical analysis.   
B. Representative TSA-IHC from 96G WTD collected at 3 MPE.  Increased PrPCWD 
immunoreactivity staining was identified in oropharyngeal lymphoid tissues in lymphoid follicle 
germinal centers.  TSA-IHC additionally detected PrPCWD immunoreactivity in the majority of 





Four MPE.  Tissues from 96G WTD sacrificed at 4 MPE had significant PrPCWD amyloid 
seeding activity in the majority of tissues evaluated with only RAMALT and VNO displaying 
variable seeding activity (Figure 2.7A). Overall, tissues had a faster rate of amyloid formation 
when compared with 3 MPE consistent with greater PrPCWD tissue accumulation.  The first 
identification of amyloid seeding activity in a 96S WTD was detected in the tonsil at this time 
point.   
 TSA-IHC analysis of 4 MPE tissues revealed PrPCWD immunoreactivity in all tissues 
from at least 2 of the 3 96G WTD examined (Figure 2.7B).  The tonsil and retropharyngeal 
lymph nodes had extensive PrPCWD immunoreactivity in lymphoid follicle germinal centers.  
Other tissues had increased PrPCWD follicle distribution compared to 3 MPE tissues and greater 
staining intensity consistent with increased prion accumulation.  No PrPCWD immunoreactivity 




Figure 2.7 4 MPE collection.  
A. RT-QuIC of WTD tissues collected at 4 MPE.  All tissues examined displayed PrPCWD 
amyloid formation detected in at least two of the three 96G WTD (one sample t-test, p<0.05).  
The two tissues that did not have significant rates of amyloid formation are 1201 vomeronasal 
organ and 1201 RAMALT.  Compared with 3 MPE (Figure 2.6), 4 MPI tissues have greater rates 
of amyloid formation consistent with a larger PrPCWD tissue burden.  Tonsil from 96S WTD had 
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detectable amyloid formation at this collection time (one sample t-test, p<0.01). Data represents 
mean and SEM of 12 replicates from 3 separate experiments.  
B. Representative TSA-IHC from 96G WTD collected at 4 MPE.  All lymphoid tissues displayed 
PrPCWD immunoreactivity in the germinal centers of follicles.  The greatest staining was 
observed in oropharyngeal lymphoid tissues.  No staining was observed in corresponding 
negative control tissues.   
 
Evaluation of PrPCWD in the obex.  The obex region of the medulla oblongata was evaluated for 
evidence of PrPCWD neuroinvasion by RT-QuIC and TSA-IHC.  No PrPCWD RT-QuIC seeding 
was detected at any collection time (Figure 2.8A).  No PrPCWD immunoreactivity was observed 
by TSA-IHC (Figure 2.8B).  This demonstrates that there is no detectable evidence of 
neuroinvasion in the time period we evaluated following mucosal prion exposure.   
 
Figure 2.8 No evidence of neuroinvasion at 4 MPE. 
A. RT-QuIC evaluation of obex samples collected from 2MPE to 4 MPE.  No evidence of 
PrPCWD amyloid seeding was detected in the obexes evaluated from early infection time points.   
B. Representative TSA-IHC of the obex collected at 4 MPE.  No PrPCWD immunoreactivity was 








Table 2.1 Summary of PrPCWD detection by RT-QuIC and IHC following mucosal 
exposure.  
RT-QuIC and TSA-IHC detected similar patterns of PrPCWD accumulation during early infection: 
initial detection in oropharyngeal lymph nodes prior to systemic lymphoid dissemination.  
Although the two assays displayed similar lymphoid distribution patterns, RT-QuIC analysis 
identified more positive tissues when compared with TSA-IHC.  Data for each tissue displayed 
as number of animals positive by detection method out of total number of animals examined.  
(Abbreviations: QuIC = RT-QuIC; IHC = TSA-IHC; Retro. LN = Retropharyngeal lymph node; 
LN= lymph node; VNO = Vomeronasal organ) 
 
Tissue 1 MPE 2 MPE 3 MPE 4 MPE 
 QuIC IHC QuIC IHC QuIC IHC QuIC IHC 
Retro. LN 2/3 0/3 3/3 2/3 2/2 2/2 3/3 3/3 
Tonsil 0/3 2/3 2/3 3/3 2/2 2/2 3/3 3/3 
Mandibular LN 0/3 0/3 2/3 0/3 2/2 2/2 3/3 3/3 
Parotid LN 1/3 1/3 1/3 0/3 1/2 1/2 3/3 2/3 
Prescapular LN 0/3 0/3 0/3 0/3 2/2 1/2 3/3 2/3 
Mesenteric LN 1/3 0/3 0/3 0/1 1/2 0/2 3/3 2/3 
Hepatogastric LN 0/3 0/3 0/3 0/3 2/2 2/2 3/3 3/3 
Ileocecocolic LN 0/3 0/2 0/3 0/3 2/2 1/2 3/3 3/3 
Spleen 0/3 0/2 0/3 0/2 2/2 1/2 3/3 2/3 
RAMALT 0/3 0/3 0/3 0/2 2/2 0/2 2/3 2/3 
VNO 0/3 N/A 0/3 N/A 2/2 N/A 2/3 N/A 
Ileum N/A 0/2 N/A 0/2 N/A 1/2 N/A 2/2 
Obex 0/3 0/3 0/3 0/3 0/2 0/2 0/3 0/3 
 
Estimation of prion burden during early CWD infection 
We have previously reported the prion concentration in the sample used to seed the RT-
QuIC reaction directly correlates with the rate of amyloid formation (26,27).  To explore the 
kinetics of PrPCWD accumulation in lymphoid tissues over the course of early infection, we 
compared the average rates of amyloid formation in lymphoid tissues from the 1-4 MPE 
collection times with those collected from 3 white-tailed deer with terminal disease (20-24 
months post-infection).   Evaluation of lymphoid tissues over time revealed two patterns.  First, 
the oropharyngeal lymph nodes, including the tonsil, retropharyngeal lymph node, and 
mandibular lymph node displayed a rapid accumulation of PrPCWD, approximating terminal 
tissue levels by 3 MPI, with no statistical difference observed between 3 MPI, 4 MPE, and the 
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terminal disease states (p< 0.05, one sample t-test) (Figure 2.9A).  Second, the parotid lymph 
node, distal gastrointestinal lymph nodes, and spleen displayed a later accumulation of PrPCWD 
and did not reach peak tissue burdens during the time course of our study (4 MPE tissues 
compared with terminal, p<0.05, one sample t-test) (Figure 2.9B).  We approximated the PrPCWD 
amyloid formation kinetics of these two lymphoid patterns by linear regression analysis and 
found no statistical difference between the rates by slope analysis of best-fit linear regression 
lines (p=0.4229, linear regression analysis).  This data confirms the lymphoid tissues examined 
have similar prion replication kinetics and that the difference in lymphoid tissue prion levels at 4 
MPE is due to the sequence of PrPCWD tissue infection, i.e. the oropharyngeal tissues were 
infected earlier than systemic lymphoid tissues, and not due to a difference in prion replication 





Figure 2.9. Estimation of lymphoid tissue prion accumulation during the course of early 
CWD infection.   
A. Estimation of prion replication kinetics in oropharyngeal lymphoid tissues during early CWD 
infection.  The prion concentration in tissues was estimated by averaging the rates of amyloid 
formation collection time point.  Two lymphoid PrPCWD accumulation patterns were observed.  
A) In orophargyneal lymph nodes, the tonsil, retropharyngeal and mandibular lymph nodes 
displayed a rapid PrPCWD accumulation and reached tissue PrPCWD tissue levels comparable with 
terminal disease burden by 3 MPE (p<0.05, one sample t-test).  The parotid lymph node had a 
slower prion accumulation but reached prion levels comparable with terminal disease by 4 MPE 
(p<0.01, one sample t-test).   
B. Estimation of prion replication kinetics in gastrointestinal-associated lymphoid tissues 
(GALT) and systemic lymphoid tissues during early CWD infection.  Distal GALT tissues and 
the spleen did not display PrPCWD seeding until 3 MPE, later than oropharyngeal lymphoid 
tissues (in A).  At 4 MPE, all tissues had significantly lower rates of amyloid formation than 
corresponding terminal tissues (p<0.01, one sample t-test), indicating these lymphoid tissues did 





 We analyzed PrPCWD distribution in WTD at early time points following oral exposure.  
Although we were unable to identify the sites of mucosal entry following PrPCWD ingestion, we 
demonstrated early PrPCWD accumulation in oropharyngeal lymph nodes at 1 MPE and rapid 
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systemic accumulation of PrPCWD in lymphoid tissues by 4 MPE with tissue prion levels 
comparable to terminal disease.  Our findings are consistent with previous investigations of early 
CWD pathogenesis (21,22) despite the exposure dose given in our study being 10-fold lower.  
This suggests either the dose of PrPCWD does not impact infection kinetics or that in all of these 
studies the given dose far surpassed the natural infectious dose resulting in the same 
experimental disease course.  A recent report determined the minimal effective oral dose of 
sheep-adapted BSE to be 0.05g and did not observe alterations in the disease course at higher 
inoculation doses (29).  Investigations into the minimum infectious oral dose required for CWD 
in the natural host are on-going.   
 Similar to other ingested TSEs, such as scrapie and variant Creutzfeldt-Jakob disease, our 
results demonstrate CWD displays and early and sustained lymphoid replication phase prior to 
neuroinvasion (30,31).  Temporal investigations of scrapie identified gastrointestinal-associated 
lymphoid tissues, including tonsil, retropharyngeal lymph node, Peyer’s patches, and 
ileocecocolic lymph nodes, as the first sites of PrPSc detection (32,33).  The pattern of lymphoid 
accumulation observed in our study is consistent with two phases.  First, the lymphoid tissues 
draining the head and neck displayed PrPCWD amyloid seeding activity and IHC 
immunoreactivity.  This is consistent with either a larger initial PrPCWD dose in these tissues due 
to direct drainage from the oral mucosa or faster PrPCWD replication kinetics.  This initial 
lymphoid replication phase was followed by widespread systemic lymphoid PrPCWD eplication, 
as evidenced by PrPCWD detection in the spleen.  PrPCWD may be trafficked from initial lymphoid 
replication sites through either blood or lymphoid cells.  Blood has been previously shown to 
harbor CWD infectivity (10) with B cells and platelets being identified as the infectious 
components (34).  In contrast, a mouse study identified macrophages as the cell responsible for 
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transporting prions from intestinal mucosa to draining lymph nodes (35).  Further studies are 
needed to illuminate which lymphoid cell or cells are responsible for systemic prion trafficking 
in subclinical chronic wasting disease.  A surprising finding was the early detection of PrPCWD 
seeding activity in the vomeronasal organ at 3 MPE.  Nasal brushings in conjunction with RT-
QuIC have recently been investigated as a potential pre-clinical diagnostic tool in humans with 
CJD and cervids (36-38).  The early PrPCWD distribution to the nasal cavity may provide a route 
of environmental shedding in preclinical animals.    
 Given the transmission of TSEs following oral exposure, investigations have focused on 
how prions cross gastrointestinal mucosal barriers.  Studies on intestinal uptake have identified 
M cells of the follicle-associated epithelium of Peyer’s patches as a site of prion entry (39,40).  
Additionally, GALT uptake appears to be required for neuroinvasion as depletion of M cells or 
decreased numbers of Peyer’s patches, but not lymphocytes, in mice blocked the development of 
prion disease (35,41-43).  Other imaging studies have suggested prions can use a paracellular 
route across the epithelial mucosa by identifying prions in between cells (40).  Our study 
identified the oropharyngeal lymph nodes, tonsil, retropharyngeal, and mandibular lymph nodes 
as an initial site of PrPCWD lymphoid accumulation after oral exposure suggesting a pathway of 
mucosal uptake in the oral cavity plays an important role in early pathogenesis.  It is possible that 
intestinal mucosal uptake also contributes to prion uptake, similar to other orally transmitted 
TSEs, but it remains unclear where the primary mucosal entry site is located and how prions 
cross oral mucosal barriers in CWD.  
At early CWD disease stages, the low prion tissue burden limits PrPCWD identification by 
traditional immunoblotting techniques.  Here, we have demonstrated both RT-QuIC and a 
modified immunohistochemistry technique, TSA-IHC, can enhance PrPCWD detection.  
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Comparison of RT-QuIC and TSA-IHC as a detection method during early infection time points 
demonstrated RT-QuIC consistently identified PrPCWD amyloid seeding in tissues approximately 
1 month prior to IHC detection.  This finding is consistent with recent literature that reported 
RT-QuIC has at least equal sensitivity as IHC in detecting PrPCWD in RAMALT biopsies from 
WTD and elk (36,37).  A larger sample size is necessary to evaluate the sensitivity and 
specificity of RT-QuIC as a diagnostic tool for PrPCWD detection in terminal lymphoid tissues.  
The variation in PrPCWD tissue detection among 96G WTD from the same collection time is 
consistent with individual animal variation and tissue sectioning differences.   
In regards to influence of the PRNP genotype on susceptibility to CWD, our study is 
consistent with previous investigations on codon 96 (17).  Lymphoid tissues from 96S WTD did 
not display the same RT-QuIC amyloid seeding activity as 96G WTD tissues and PrPCWD was 
only detected in tonsil collected at 4 MPI.  The slower disease course in 96S WTD may be better 
able to distinguish the chronological sequence of PrPCWD lymphoid replication that is otherwise 
masked in the faster 96G WTD disease course.  Thus, identification of amyloid seeding in tonsil 
suggests this tissue might be the first location of PrPCWD seeding and replication following oral 
exposure.  However, the small number of animals available for our study makes these 
conclusions tentative.     
 In summary, we used RT-QuIC and TSA-IHC to illustrate lymphoid seeding and 
replication in oropharyngeal lymphoid tissues as early as 1 month following oral CWD exposure.  
This initial lymphoid replication phase was followed by PrPCWD replication in systemic lymphoid 
tissues with tissue burdens approximating terminal disease levels by 4 months post-exposure.  
Similar to other orally acquired TSEs, prion lymphoid amplification appears to occur prior to 




 Future studies will examine the remaining systemic and lymphoid tissues collected at 4 
MPE to determine the full-body distribution of PRPCWD at this early time point.  We will use a 
new end-point RT-QuIC technique for this whole-animal survey.  In addition, we plan on 
evaluating excreta, including saliva and urine, from these early collection time points to 









1. Williams, E. S. (2005) Chronic wasting disease. Veterinary pathology 42, 530-549 
2. Haley, N. J., and Hoover, E. A. (2015) Chronic wasting disease of cervids: current 
knowledge and future perspectives. Annu Rev Anim Biosci 3, 305-325 
3. ProMED-mail. (2016) Chronic Wasting Disease, Cervid - Europe: (Norway). ProMed-
mail 20160410.4149651 
4. Williams, E. S., and Young, S. (1980) Chronic wasting disease of captive mule deer: a 
spongiform encephalopathy. Journal of wildlife diseases 16, 89-98 
5. Spraker, T. R., Miller, M. W., Williams, E. S., Getzy, D. M., Adrian, W. J., Schoonveld, 
G. G., Spowart, R. A., O'Rourke, K. I., Miller, J. M., and Merz, P. A. (1997) Spongiform 
encephalopathy in free-ranging mule deer (Odocoileus hemionus), white-tailed deer 
(Odocoileus virginianus) and Rocky Mountain elk (Cervus elaphus nelsoni) in 
northcentral Colorado. Journal of wildlife diseases 33, 1-6 
6. Williams, E. S., and Young, S. (1993) Neuropathology of chronic wasting disease of 
mule deer (Odocoileus hemionus) and elk (Cervus elaphus nelsoni). Veterinary pathology 
30, 36-45 
7. Spraker, T. R., Zink, R. R., Cummings, B. A., Wild, M. A., Miller, M. W., and O'Rourke, 
K. I. (2002) Comparison of histological lesions and immunohistochemical staining of 
proteinase-resistant prion protein in a naturally occurring spongiform encephalopathy of 
free-ranging mule deer (Odocoileus hemionus) with those of chronic wasting disease of 
captive mule deer. Veterinary pathology 39, 110-119 
8. Miller, M. W., Williams, E. S., Hobbs, N. T., and Wolfe, L. L. (2004) Environmental 
sources of prion transmission in mule deer. Emerg Infect Dis 10, 1003-1006 
9. Mathiason, C. K., Hays, S. A., Powers, J., Hayes-Klug, J., Langenberg, J., Dahmes, S. J., 
Osborn, D. A., Miller, K. V., Warren, R. J., Mason, G. L., and Hoover, E. A. (2009) 
Infectious prions in pre-clinical deer and transmission of chronic wasting disease solely 
by environmental exposure. PloS one 4, e5916 
10. Mathiason, C. K., Powers, J. G., Dahmes, S. J., Osborn, D. A., Miller, K. V., Warren, R. 
J., Mason, G. L., Hays, S. A., Hayes-Klug, J., Seelig, D. M., Wild, M. A., Wolfe, L. L., 
Spraker, T. R., Miller, M. W., Sigurdson, C. J., Telling, G. C., and Hoover, E. A. (2006) 
Infectious prions in the saliva and blood of deer with chronic wasting disease. Science 
314, 133-136 
11. Tamguney, G., Miller, M. W., Wolfe, L. L., Sirochman, T. M., Glidden, D. V., Palmer, 
C., Lemus, A., DeArmond, S. J., and Prusiner, S. B. (2009) Asymptomatic deer excrete 
infectious prions in faeces. Nature 461, 529-532 
12. Haley, N. J., Seelig, D. M., Zabel, M. D., Telling, G. C., and Hoover, E. A. (2009) 
Detection of CWD prions in urine and saliva of deer by transgenic mouse bioassay. PloS 
one 4, e4848 
13. Johnson, C. J., Phillips, K. E., Schramm, P. T., McKenzie, D., Aiken, J. M., and 
Pedersen, J. A. (2006) Prions adhere to soil minerals and remain infectious. PL S 
pathogens 2, e32 
14. Nalls, A. V., McNulty, E., Powers, J., Seelig, D. M., Hoover, C., Haley, N. J., Hayes-
Klug, J., Anderson, K., Stewart, P., Goldmann, W., Hoover, E. A., and Mathiason, C. K. 
79 
 
(2013) Mother to offspring transmission of chronic wasting disease in reeves' muntjac 
deer. PloS one 8, e71844 
15. Robinson, S. J., Samuel, M. D., O'Rourke, K. I., and Johnson, C. J. (2012) The role of 
genetics in chronic wasting disease of North American cervids. Prion 6, 153-162 
16. Johnson, C., Johnson, J., Clayton, M., McKenzie, D., and Aiken, J. (2003) Prion protein 
gene heterogeneity in free-ranging white-tailed deer within the chronic wasting disease 
affected region of Wisconsin. Journal of wildlife diseases 39, 576-581 
17. Johnson, C. J., Herbst, A., Duque-Velasquez, C., Vanderloo, J. P., Bochsler, P., Chappell, 
R., and McKenzie, D. (2011) Prion protein polymorphisms affect chronic wasting disease 
progression. PloS one 6, e17450 
18. Race, B., Meade-White, K., Miller, M. W., Fox, K. A., and Chesebro, B. (2011) In vivo 
comparison of chronic wasting disease infectivity from deer with variation at prion 
protein residue 96. Journal of virology 85, 9235-9238 
19. van Keulen, L. J., Vromans, M. E., and van Zijderveld, F. G. (2002) Early and late 
pathogenesis of natural scrapie infection in sheep. APMIS : acta pathologica, 
microbiologica, et immunologica Scandinavica 110, 23-32 
20. O'Rourke, K. I., Zhuang, D., Lyda, A., Gomez, G., Williams, E. S., Tuo, W., and Miller, 
M. W. (2003) Abundant PrP(CWD) in tonsil from mule deer with preclinical chronic 
wasting disease. Journal of veterinary diagnostic investigation : official publication of 
the American Association of Veterinary Laboratory Diagnosticians, Inc 15, 320-323 
21. Sigurdson, C. J., Williams, E. S., Miller, M. W., Spraker, T. R., O'Rourke, K. I., and 
Hoover, E. A. (1999) Oral transmission and early lymphoid tropism of chronic wasting 
disease PrPres in mule deer fawns (Odocoileus hemionus). The Journal of general 
virology 80 ( Pt 10), 2757-2764 
22. Fox, K. A., Jewell, J. E., Williams, E. S., and Miller, M. W. (2006) Patterns of PrPCWD 
accumulation during the course of chronic wasting disease infection in orally inoculated 
mule deer (Odocoileus hemionus). The Journal of general virology 87, 3451-3461 
23. Hunter, N., Houston, F., Foster, J., Goldmann, W., Drummond, D., Parnham, D., 
Kennedy, I., Green, A., Stewart, P., and Chong, A. (2012) Susceptibility of young sheep 
to oral infection with bovine spongiform encephalopathy decreases significantly after 
weaning. Journal of virology 86, 11856-11862 
24. Stewart, P., Campbell, L., Skogtvedt, S., Griffin, K. A., Arnemo, J. M., Tryland, M., 
Girling, S., Miller, M. W., Tranulis, M. A., and Goldmann, W. (2012) Genetic 
predictions of prion disease susceptibility in carnivore species based on variability of the 
prion gene coding region. PloS one 7, e50623 
25. Seelig, D. M., Nalls, A. V., Flasik, M., Frank, V., Eaton, S., Mathiason, C. K., and 
Hoover, E. A. (2015) Lesion profiling and subcellular prion localization of cervid chronic 
wasting disease in domestic cats. Veterinary pathology 52, 107-119 
26. Henderson, D. M., Davenport, K. A., Haley, N. J., Denkers, N. D., Mathiason, C. K., and 
Hoover, E. A. (2015) Quantitative assessment of prion infectivity in tissues and body 
fluids by real-time quaking-induced conversion. The Journal of general virology 96, 210-
219 
27. Henderson, D. M., Denkers, N. D., Hoover, C. E., Garbino, N., Mathiason, C. K., and 
Hoover, E. A. (2015) Longitudinal Detection of Prion Shedding in Saliva and Urine by 
Chronic Wasting Disease-Infected Deer by Real-Time Quaking-Induced Conversion. 
Journal of virology 89, 9338-9347 
80 
 
28. Davenport, K. A., Henderson, D. M., Bian, J., Telling, G. C., Mathiason, C. K., and 
Hoover, E. A. (2015) Insights into Chronic Wasting Disease and Bovine Spongiform 
Encephalopathy Species Barriers by Use of Real-Time Conversion. Jour al of virology 
89, 9524-9531 
29. McGovern, G., Martin, S., Jeffrey, M., Dexter, G., Hawkins, S. A., Bellworthy, S. J., 
Thurston, L., Algar, L., and Gonzalez, L. (2016) Minimum Effective Dose of Cattle and 
Sheep BSE for Oral Sheep Infection. PloS one 11, e0151440 
30. Mabbott, N. A., and MacPherson, G. G. (2006) Prions and their lethal journey to the 
brain. Nat Rev Microbiol 4, 201-211 
31. Beekes, M., and McBride, P. A. (2007) The spread of prions through the body in 
naturally acquired transmissible spongiform encephalopathies. Th  FEBS journal 274, 
588-605 
32. van Keulen, L. J., Schreuder, B. E., Vromans, M. E., Langeveld, J. P., and Smits, M. A. 
(2000) Pathogenesis of natural scrapie in sheep. Archives of virology. Supplementum, 57-
71 
33. Hadlow, W. J., Kennedy, R. C., and Race, R. E. (1982) Natural infection of Suffolk sheep 
with scrapie virus. The Journal of infectious diseases 146, 657-664 
34. Mathiason, C. K., Hayes-Klug, J., Hays, S. A., Powers, J., Osborn, D. A., Dahmes, S. J., 
Miller, K. V., Warren, R. J., Mason, G. L., Telling, G. C., Young, A. J., and Hoover, E. 
A. (2010) B cells and platelets harbor prion infectivity in the blood of deer infected with 
chronic wasting disease. Journal of virology 84, 5097-5107 
35. Takakura, I., Miyazawa, K., Kanaya, T., Itani, W., Watanabe, K., Ohwada, S., Watanabe, 
H., Hondo, T., Rose, M. T., Mori, T., Sakaguchi, S., Nishida, N., Katamine, S., 
Yamaguchi, T., and Aso, H. (2011) Orally administered prion protein is incorporated by 
m cells and spreads into lymphoid tissues with macrophages in prion protein knockout 
mice. The American journal of pathology 179, 1301-1309 
36. Haley, N. J., Siepker, C., Hoon-Hanks, L. L., Mitchell, G., Walter, W. D., Manca, M., 
Monello, R. J., Powers, J. G., Wild, M. A., Hoover, E. A., Caughey, B., and Richt, J. A. 
(2016) Seeded amplification of chronic wasting disease prions in nasal brushings and 
recto-anal mucosa associated lymphoid tissues from elk by real time quaking-induced 
conversion. Journal of clinical microbiology  
37. Haley, N. J., Siepker, C., Walter, W. D., Thomsen, B. V., Greenlee, J. J., Lehmkuhl, A. 
D., and Richt, J. A. (2016) Antemortem detection of chronic wasting disease prions in 
nasal brush collections and rectal biopsies from white-tailed deer by real time quaking-
induced conversion. Journal of clinical microbiology  
38. Orru, C. D., Bongianni, M., Tonoli, G., Ferrari, S., Hughson, A. G., Groveman, B. R., 
Fiorini, M., Pocchiari, M., Monaco, S., Caughey, B., and Zanusso, G. (2014) A test for 
Creutzfeldt-Jakob disease using nasal brushings. The New England journal of medicine 
371, 519-529 
39. Kujala, P., Raymond, C. R., Romeijn, M., Godsave, S. F., van Kasteren, S. I., Wille, H., 
Prusiner, S. B., Mabbott, N. A., and Peters, P. J. (2011) Prion uptake in the gut: 
identification of the first uptake and replication sites. PLoS pathogens 7, e1002449 
40. Kincaid, A. E., Hudson, K. F., Richey, M. W., and Bartz, J. C. (2012) Rapid 




41. Donaldson, D. S., Kobayashi, A., Ohno, H., Yagita, H., Williams, I. R., and Mabbott, N. 
A. (2012) M cell-depletion blocks oral prion disease pathogenesis. Mucosal Immunol 5, 
216-225 
42. Prinz, M., Huber, G., Macpherson, A. J., Heppner, F. L., Glatzel, M., Eugster, H. P., 
Wagner, N., and Aguzzi, A. (2003) Oral prion infection requires normal numbers of 
Peyer's patches but not of enteric lymphocytes. The American journal of pathology 162, 
1103-1111 
43. Glaysher, B. R., and Mabbott, N. A. (2007) Role of the GALT in scrapie agent 












Traditional diagnostic detection of chronic wasting disease (CWD) relies on 
immunodetection of misfolded CWD prion protein (PrPCWD) by western blotting, ELISA, or 
immunohistochemistry (IHC).  These techniques require separate sample collections (frozen and 
fixed) which may result in discrepancies due to variation in prion tissue distribution and assay 
sensitivities that limit detection especially in early and subclinical infections.  Here, we harness 
the power of real-time quaking induced conversion (RT-QuIC) to amplify, detect, and quantify 
prion amyloid seeding activity in fixed paraffin-embedded (FPE) tissue sections.  We show that 
FPE RT-QuIC has greater detection sensitivity than IHC in tissues with low PrPCWD burdens, 
including those that are IHC-negative.  We also employ amyloid formation kinetics to yield a 
semi-quantitative estimate of prion concentration in a given FPE tissue.  We report that FPE RT-
QuIC has the ability to enhance diagnostic and investigative detection of disease-associated 




 Prion diseases, or transmissible spongiform encephalopathies, are fatal 
neurodegenerative diseases that include Creutzfeldt-Jakob disease (CJD) in humans, bovine 
spongiform encephalopathy (BSE), sheep scrapie, and cervid chronic wasting disease (CWD).   
 
1Chapter published as: Hoover CE, Davenport KA, Henderson DM, Pulscher LA, Mathiason 
CK, Zabel MD, Hoover EA. Detection and Quantification of CWD Prions in Fixed Paraffin 
Embedded Tissues by Real-Time Quaking-Induced Conversion.  Sci Rep. May 9, 2016. 6:25098 
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Disease is initiated when a misfolded isoform (designated PrPSc, PrPRES, PrPCWD, or PrPD) 
induces templated misfolding of the normal cellular prion protein (PrPC) to propagate via a 
process of seeded polymerization (1,2).  Prions are characterized by increased formation of  
sheets, propensity to aggregate into amyloid fibrils, and resistance to protease and acid digestion 
(3-5).  Typical histologic lesions include spongiform neuropathology and neurodegeneration 
associated with deposition of PrPSc, and reactive astrogliosis (4).   
 Definitive diagnosis of CWD traditionally relies on detection of PrPCWD by 
immunohistochemistry (IHC), western blot (WB), enzyme-linked immunosorbent assay 
(ELISA), or animal bioassay.  The tissues tested typically include antemortem biopsies of tonsil 
or rectal associated mucosal lymphoid tissue (RAMALT) or postmortem sampling of the obex 
region of the brainstem.  Analysis by these techniques requires a minimum of two separate tissue 
samples, formalin fixed tissues for IHC and fresh or frozen tissues for WB and ELISA that can 
create result disparity in results if PrPCWD is not homogenously distributed or at low levels.  
While immunodetection methods can provide qualitative estimation of prion concentration, 
calculating the infectious titer of a prion tissue sample requires an end-point dilution bioassay, 
which relies on disease incubation time to determine infectivity levels.  Bioassay limitations 
include animal availability, cost, and time required (often greater than one year to complete).  
Cell culture based assays have been developed to supplant animal bioassays (6,7), but remain 
relatively time consuming, may be limited to specific prion strains, and are not suitable for fixed 
tissue samples.    
 Previous studies have established protocols for the isolation of disease associated prion 
proteins from formalin-fixed paraffin-embedded tissue sections 8-10.  Transgenic mice expressing 
hamster PrPC intracerebrally inoculated with prions isolated from formaldehyde fixed paraffin-
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embedded 263K scrapie strain terminal brains developed clinical disease(8).  Prion protein can 
be demonstrated in some archived formalin-fixed paraffin-embedded tissues and detected by 
western blotting, albeit with lower levels of sensitivity, typically limiting this method to terminal 
samples (9,10).  A separate protein blotting technique, the paraffin embedded tissue blot, can 
detect PrPD deposition in the brain of pre-clinical animals by using harsh epitope retrieval and 
immunostaining; however, the multi-step process is labor intensive and cannot provide 
quantitative data (11).   
 In most samples collected prior to terminal disease, PrPCWD levels are often below the 
threshold of detection by IHC or WB; thus detection at these time points requires in vitro
amplification methods for detection (12-15).  One amyloid amplification method is real time 
quaking induced conversion (RT-QuIC), which utilizes templated prion seeded conversion of 
bacterially expressed recombinant PrPC into amyloid structures that are measured by thioflavin T 
(ThT) fluorescence (15).  Repeated cycles of shaking are used to exponentially increase initial 
low levels of PrPCWD, potentially facilitating a greater sensitivity of detection.  In addition, RT-
QuIC amyloid formation kinetics have been adapted to estimate the low quantity of prions in 
samples of body fluids and excreta (16,17) with a sensitivity approaching bioassay (14). 
 Here, we describe a simple and rapid technique to detect and quantify PrPCWD p ion 
seeding activity from fixed paraffin-embedded (FPE) tissues by RT-QuIC.  Assessment of RT-
QuIC amyloid formation rate kinetics enabled quantification of PrPCWD, providing a useful 
estimation of prion infectivity in IHC positive tissues.  The combination of IHC and FPE RT-
QuIC makes possible the description of PrPCWD distribution and estimation of the infectious titer 







Hand-raised, indoor-adapted white-tailed deer (WTD) (Odocoileus virginianus) were 
provided through long-standing collaboration of David Osborn, Sallie Dahmes, Karl Olsen, and 
Robert Warren, at the Warnell School of Forestry and Natural Resources, University of Georgia.  
Deer were housed in an indoor research facility at Colorado State University.  Institutional 
Animal Care and Use Committee (IACUC) protocols for animal treatment and handling were 
followed.  All animal studies were approved by Colorado State University IACUC.  Archived 
tissues from CWD-infected WTD were used to optimize these techniques.  All WTD with 800-
series ID numbers were intranasally inoculated with two 1 mL doses of a 5% CWD positive 
brain homogenate (18).  Deer were allowed to develop clinical disease and tissues were collected 
at terminal necropsy.  All deer with 11-series and 12-series ID numbers were inoculated per os 
with 0.5 grams of a CWD positive pool of cervid brain.  Deer were sacrificed, necropsied, and 
tissues collected at scheduled monthly intervals post-inoculation prior to development of clinical 
signs associated with CWD infection.      
Tissue processing 
At necropsy, all tissues were individually collected with a prion-free instruments to 
prevent cross contamination and were divided in half with one half stored at -80°C until use and 
the other half fixed for a minimum of 48 hours in periodate-lysine-paraformaldehyde (PLP) 
fixative.  After 48 hours tissues were transferred to sterile 1xPBS until trimming and then stored 
in 70% ethanol.  Sections of the obex region of the medulla oblongata, retropharyngeal lymph 
node, and tonsil were trimmed and subjected to routine paraffin embedding. Frozen tissues were 
homogenized in 1xPBS at 10% weight per volume with a Blue BulletTM bead-beater 
86 
 
homogenizer (Next Advance) with care to avoid any cross contamination among tissue 
homogenates.   
Protein extraction from FPE blocks 
Eight to 10 μm thick paraffin-embedded tissue wax curls were cut from paraffin blocks 
using a microtome (Leica) with a prion-free microtome blade and prion-free forceps for every 
FPE sample to avoid cross contamination.  Paraffin-tissue curls were subjected to a series of 
xylene and graded alcohol washes (100%, 95%, and 70%) to remove paraffin and rehydrate 
tissues similar to standard histological methods.  Following alcohol treatments rehydrated FPE 
tissues were washed with 1xPBS.  Rehydrated FPE tissue was homogenized in at 10% weight 
per volume by manual disruption or a bead homogenizer as described above.   
Immunohistochemistry for PrPCWD 
Following routine paraffin embedding, 5 μm microtome tissue sections were placed on 
positively charged glass slides.  Tissues were deparaffinized, rehydrated with graded alcohols, 
and treated with 88% formic acid digestion prior to heat-induced epitope antigen retrieval in the 
2100-RetrieverTM (Prestige Medical).  Following retrieval, endogenous peroxidase activity was 
quenched prior to prion epitope detection with anti-prion antibody BAR224 (Cayman chemical) 
at β μg/mL concentration and Envision+TM anti-mouse HRP-labeled polymer (Dako).  Following 
antibody treatment, antigen was visualized with 3-amino-9-ethylcarbazole (AEC) substrate 
chromogen (Dako).  Tissue sections were counterstained with Meyer’s hematoxylin (Dako) and 
0.1% bicarbonate bluing reagent prior to coverslipping with aqueous mounting media (Dako).   
Recombinant Syrian hamster PrPC protein purification 
Purification was performed as previously described (14,16,19).  Briefly, recombinant 
truncated Syrian hamster PrPC (90-231) (SHrPrP) was expressed and purified from BL21 Rosetta 
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(Novagen) Escherichia coli.  Cells from a glycerol stock were cultured at 37°C in lysogeny broth 
(LB) media with selection antibiotics kanamycin and chloramphenicol until the final OD600 was 
at least 2.5.  Cell lysis was performed using BugbusterTM reagent, supplemented with 
LysonaseTM (EMD Biosciences) and inclusion bodies harvested by centrifugation at 15,000 x g.  
Inclusion bodies were dissolved in solubilization buffer (8M guanidine hydrochloride, 100mM 
Na2HPO4) and applied to NiNTA superflow resin (Qiagen) that had been equilibrated with 
denaturation buffer (6M guanidine hydrochloride, 100mM Na2HPO4, 10mM Tris).  The resin-
SHrPrP was loaded on to a XK16-60 column (GE Healthcare) and purified using a Bio-Rad 
DuoflowTM FPLC.  A gradient from denaturation buffer to refolding buffer (100mM Na2HPO4, 
10mM Tris) was applied to induce protein refolding prior to a wash with refolding buffer.  
Refolding was followed by a gradient from refolding to elution buffer (100mM NaH2PO4, 10mM 
Tris, 0.5 M imidazole) and all fractions were collected.  The fractions from the elution peak were 
pooled and dialyzed (20mM NaH2PO4) overnight.  Protein concentration was calculated by 
measuring the A280 and using a coefficient of extinction of 25,900 in Beer’s Law.   
RT-QuIC assay 
Assay conditions were as previously described (16,17).  FPE tissue homogenates or 10% 
frozen tissue homogenates were diluted in 0.1% sodium dodecyl sulfate (SDS)/ 1xPBS buffer as 
described.  For subclinical WTD samples, a 10-1 dilution of FPE homogenates was used to seed 
the RT-QuIC reaction.  Two μL of diluted sample was added to the RT-QuIC reaction buffer 
consisting of 20mM NaH2PO4, 320mM NaCl, 1.0mM EDTA, 1mM Thioflavin T (ThT) and 0.1 
mg/mL SHrPrP.  RT-QuIC reactions were carried out in black, optical bottom 96-well plates 
(Nunc) in a BMG Labtech PolarstarTM fluorometer.  RT-QuIC cycles consisted of 1 minute of 
shaking at 700 rpm followed by 1 minute of rest, repeated for 15 minutes.  Fluorescence was 
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read at the conclusion of each 15 minute shake/rest cycle with an excitation of 450 nm and 
emission of 480 nm, gain of 1700, and each well was measured with 20 flashes per well with an 
orbital averaging of 4.  Each RT-QuIC assay was performed for 250 cycles, the equivalent of 
62.5 hours.   
CWD bioassay in transgenic cervidized mice 
All mice were bred and maintained at Colorado State University Lab Animal Resources, 
accredited by the Association for Assessment and Accreditation of Lab Animal Care 
International in accordance with protocols approved by the Institutional Animal Care and Use 
Committee at Colorado State University.  All animal studies were approved by Colorado State 
University IACUC.  Transgenic mice overexpressing the cervid cellular prion protein were 
inoculated with 30 µL of a homogenate pooled from six terminal experimentally inoculated 
WTD brain samples (cervid brain pool 6; CBP6) diluted from 1.0% to 0.00001% concentration.  
Mice were observed for clinical signs and sacrificed when they reached terminal disease.  Mice 
that did not develop clinical signs were sacrificed at 500 days post inoculation when the study 
was terminated.  Brains were harvested from all animals at time of sacrifice and analyzed for 
PrPCWD by immunohistochemistry following the above protocol or western blot (20).   
 
 
RT-QuIC rate analysis and quantification 
The time to threshold, or Ct values, were calculated by determining the time (hours) for a 
positive amyloid seeding reaction to reach a predetermined threshold (established as 5 standard 
deviations above the average baseline fluorescence of all samples).  The rate of amyloid 
formation was calculated as the inverse of the Ct value (1/h).  FPE RT-QuIC amyloid formation 
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rates for each sample were confirmed to be normally distributed using the D’Agostino-Pearson 
normality test.  RT-QuIC amyloid formation rates were statistically compared with 
corresponding negative controls using a one-sample t test.  An equation relating the amyloid 
formation rate (1/h) to the LD50 for mouse bioassayed material (CBP6) was created by applying 
a best-fit line to the linear range, 10-4 to 10-6, of the RT-QuIC CBP6 dilution.  This equation, in 





Detection of PrPCWD in FPE brain samples 
 RT-QuIC is a prion-seeded amyloid amplification assay that uses recombinant PrPC as 
the substrate and thioflavin T (ThT) amyloid-binding fluorescence emission as the indicator of 
prion enciphered amyloid fibril formation (21).  RT-QuIC generation of prion seeded amyloid 
fibril formation follows a logarithmic pattern, with an early lag phase below the level of ThT 
detection and a rapid exponential phase as amyloid fibrils are formed, analogous to DNA 
replication in PCR reactions (Fig 3.1a).  A positive RT-QuIC reaction is defined as when a ThT 
fluorescence curve crosses an established baseline threshold, calculated to be five standard 
deviations above the average initial fluorescence.  The time for a reaction to reach the threshold 
is defined as the Ct value (hours).  Since ThT fluorescence is recorded in real time, the rate of 
amyloid formation can be calculated as the inverse of the Ct value (1/h).  Previous studies have 
demonstrated a direct, linear relationship between the Ct value and concentration of prions in the 
sample used to seed a reaction.  Thus, samples with larger prion burdens have greater amyloid 






Figure 3.1 Overview of methods.   
(a) Representative RT-QuIC fluorescence curve.  As prion-enciphered amyloid is formed out of 
rPrPC substrate the RT-QuIC reaction transitions from lag phase to exponential phase.  Amyloid 
formation is measured through thioflavin T (ThT) fluorescence emission as it binds amyloid.  
The Ct value is defined as the time (hours) for a positive RT-QuIC reaction to reach a predefined 
threshold (horizontal line), indicated by the red circle.  The rate of amyloid formation is 
calculated as the inverse of Ct (1/h).  
(b) Schematic of FPE protein extraction method.   
91 
 
To determine if our FPE protein extraction method preserved PrPCWD amyloid seeding 
activity for RT-QuIC detection, we selected the obex portion of the medulla oblongata region of 
the brainstem from white-tailed deer (WTD) infected with CWD by an aerosol route.  This 
region had marked PrPCWD deposition demonstrated by IHC (Figure 3.2a) (18).  Obex samples 
from sham-inoculated WTD were processed in parallel as negative controls.  Microtome paraffin 
shavings of 8 to 10 µm thickness from FPE tissue blocks were treated with a series of xylene and 
alcohol washes to remove paraffin and rehydrate the tissue sections consistent with conventional 
histologic section processing.  Following tissue rehydration, extracted samples were weighed and 
converted into a 10% weight per volume homogenate to standardize the amount of sample 
analyzed by RT-QuIC (Fig 3.1b).   
Serial dilutions from 10-1 to 10-8 were analyzed comparing the FPE-extracted obex 
sample homogenates to the corresponding unfixed, frozen obex sample homogenates collected at 
necropsy from the same animal.  All WTD inoculated with CWD had marked, variably sized 
PrPCWD plaque accumulation and neuropil vacuolation in the obex by IHC consistent with 
terminal disease pathology (Figure 3.2a).  No PrPCWD immunoreactivity was observed in the 
corresponding negative control obex samples.  RT-QuIC ThT fluorescence readings were 
converted to rates of amyloid formation by calculating the Ct value.  The dilutional series data 
demonstrated that the FPE obex homogenates maintained prion amyloid seeding activity over a 
10-1 to 10-7 dilution range (Figure 3.2b).  By comparison, dilution of parallel frozen unfixed obex 
homogenates from the same animal contained prion seeding activity from dilutions 10-3 to 10-8.  
The absence of RT-QuIC amyloid seeding activity in 10-1 and 10-2 dilutions of unfixed frozen 
samples is well documented and believed to be the result of inhibitors present in high 
concentrations in nervous tissue homogenates, which must be diluted before amyloid formation 
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can occur (22).  Background, spontaneous unseeded amyloid formation from rPrPC substrate was 
rare in negative control obex homogenates derived from either FPE or unfixed frozen obex 
samples and comparable between the two sample preparation techniques.  These results 
demonstrated that the FPE RT-QuIC protocol can consistently and specifically detect PrPCWD 




Figure 3.2 Detection of amyloid seeding activity in FPE obex tissue.   
(a) Immunohistochemistry of obex from three terminal white-tailed deer.  All display variably 
sized PrPCWD plaque accumulations in the neuropil.  The corresponding negative control 
animals do not display any PrPCWD immunoreactivity.  Images are 400x magnification, 
measurement bars represent β0 μm. 
(b) RT-QuIC rates of amyloid formation of serial dilutions of FPE tissues from IHC positive 
obex and frozen 10% obex tissue homogenate.  FPE samples from IHC positive obex are 
detectable in RT-QuIC from all three white-tailed deer examined.  The RT-QuIC linear range 
in FPE obex samples extends from 10-1 to 10-6 whereas the linear range in frozen 10% 
homogenates is from 10-4 to 10-7.  Spontaneous amyloid formation from rPrPC negative control 
samples occurred equally rarely in both FPE and frozen homogenates.  Each point represents 
median and interquartile range (IQR) and is derived of 8 replicates from a minimum of two 
separate experiments. 
 
Detection of PrPCWD seeding activity in FPE retropharyngeal lymph node 
 Next, we examined retropharyngeal lymph nodes from the same WTD analyzed in Figure 
2 using identical FPE protein extraction methodology.  Retropharyngeal lymph nodes from WTD 
inoculated with CWD displayed moderate to marked PrPCWD deposition in germinal centers of 
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lymphoid follicles by IHC consistent with a CWD disease state (Figure 3a).  By comparison, 
retropharyngeal lymph nodes from corresponding negative control WTD did not display any 
PrPCWD immunoreactivity.  Both FPE and frozen lymph node homogenates displayed amyloid 
seeding activity over dilutions 10-1 to 10-5 revealing lower endpoints and less inhibitor activity 
when compared to nervous tissue (Figure 3.3b).  These results confirmed that the FPE protein 
extraction protocol is applicable to demonstrating amyloid seeding activity in FPE lymphoid 
tissues of WTD.     
Figure 3.3 Detection of amyloid seeding activity in FPE retropharyngeal lymph node.   
(a) Immunohistochemistry of retropharyngeal lymph nodes from three terminal white-tailed 
deer.  Mild to marked PrPCWD immunoreactivity is present in germinal centers of lymphoid 
follicles.  No PrPCWD immunoreactivity is detected in negative control animals.  All IHC 
images are 200x magnification, measurement bars represent β0 μm.   
(b) RT-QuIC of serial dilutions of terminal-disease, IHC positive FPE retropharyngeal lymph 
node and 10% frozen homogenate.  Similar to obex samples (see Fig 2), RT-QuIC successfully 
detected amyloid seeding activity in FPE retropharyngeal lymph node samples.  The range of 
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detection was similar between FPE samples and frozen samples, generally from 10-1 to 10-5.  
Spontaneous amyloid formation was rare in negative controls and did not differ between FPE 
and frozen samples.  Each point represents median and IQR and is derived of 8 replicates from 
a minimum of two separate experiments.  
 
Sensitivity of RT-QuIC prion seeding activity detection in FPE tissues  
 We sought to estimate the sensitivity of FPE RT-QuIC seeding and concurrently 
determine whether prion-related amyloid seeding could be detected in IHC-negative tissues from 
CWD inoculated WTD due to RT-QuIC amplification of initial prion seeds.  We selected tonsil 
and retropharyngeal lymph node samples from subclinical WTD that were orally inoculated with 
CWD and sacrificed at either two or four months post-inoculation (MPI).  At these collection 
times, PrPCWD was variably detectable by IHC in retropharyngeal lymph nodes and tonsils 
(summarized in Table 1).  At 2 MPI, minimal or no PrPCWD immunoreactivity was observed in 
tissues and was characterized by faint granular staining in germinal centers and limited lymphoid 
follicle distribution (Figure 4a).  By contrast, at 4 MPI both lymphoid tissues displayed strong 
PrPCWD IHC immunoreactivity with dense granular staining affecting the majority of the 
follicles.  FPE RT-QuIC of tonsil and retropharyngeal lymph nodes from both subclinical time 
points (2 and 4 MPI) demonstrated amyloid seeding activities that were significantly different 
than corresponding FPE negative control tissues (One sample t-test, p<0.01) (Figure 4b).  
Tissues from 2 MPI had lower rates of amyloid formation, correlating with the minimal or absent 
PrPCWD deposition observed by IHC.  Likewise, higher amyloid formation rates were present in 4 
MPI tissues, correlating with the marked PrPCWD distribution noted by IHC.  There were no 
significant differences between the amyloid formation rates of tonsil or retropharyngeal lymph 
nodes collected at the same MPI from WTD (p<0.05, 2 MPI one sample t-test, 4 MPI one-way 
ANOVA).  These results demonstrated correlation of FPE RT-QuIC amyloid formation rates 
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with PrPCWD detection by IHC.  Additionally, we detectd prion-related amyloid seeding activity 
in FPE samples at or below the threshold of IHC detection at 2 MPI. 
 
Figure 3.4 Analysis of FPE lymphoid tissues from subclinical CWD-infected WTD by RT-
QuIC.   
(a) Representative IHC of FPE lymphoid tissues from subclinical, CWD-infected WTD.  
Tissues collected at 4 MPI have increased density of PrPCWD staining when compared to 2 MPI 
tissues reflecting a greater prion accumulation over the disease course.  The low-level of 
PrPCWD staining at 2 MPI reflects the early course of disease.  RT-QuIC detected amyloid 
seeding activity in FPE samples that are IHC negative (1148 Retro LN).  All IHC images are 
200x magnification, measurement bars represent 50 μm.   
(b) RT-QuIC of subclinical WTD retropharyngeal lymph nodes.  All retropharyngeal lymph 
nodes from subclinical animals displayed significant amyloid seeding activity (means analyzed 
by one sample t-test; ** = p< 0.01, *** = p<0.001) when compared with respective negative 
control tissues.  Lymph nodes collected at 4 MPI had higher RT-QuIC amyloid formation rates 
than tissues collected at 2 MPI which is consistent with greater PrPCWD amyloid seeding 
activity.  Each point represents the mean and SEM derived from eight replicates and in two 
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separate experiments. All FPE samples are assayed at a 10-1 dilution. 
(c) RT-QuIC of subclinical WTD tonsils.  All tonsils from subclinical animals displayed 
significant amyloid seeding activity (means analyzed by one sample t-test; *** = p< 0.001) 
when compared with respective negative control tissues.  Similar to the retropharyngeal lymph 
nodes in b, tonsils collected at 4 MPI had higher RT-QuIC amyloid formation rates than tissues 
collected at 2 MPI which is consistent with greater PrPCWD amyloid seeding activity.  Each 
point represents the mean and SEM derived from eight replicates and in two separate 
experiments. All FPE samples are assayed at a 10-1 dilution. 
 
Table 3.1 Summary of PrPCWD IHC immunoreactivity in lymphoid tissues of subclinical 
WTD. 
The number of lymphoid follicle germinal centers with PrPCWD immunoreactivity out of the 
total number of follicles in the sections examined.  This gives a general comparison of how 
much PrPCWD is present in the tissue by IHC analysis.  (LN = lymph node) 
 
WTD Tonsil Retropharyngeal LN 
1171 (4 MPI) 104/129 70/112 
1201 (4 MPI) 146/183 177/232 
1215 (4 MPI) 151/191 183/216 
1148 (2 MPI) 8/134 0/95 
1157 (2 MPI) 5/125 1/99 
 
Correlation of RT-QuIC reaction rate with bioassay 
 To establish a biological correlation between the amyloid formation rate and an estimated 
tissue prion burden, we analyzed the RT-QuIC rate from a dilutional series of a deer brain 
homogenate that was assayed by cervid PrPC transgenic mouse end-point dilutional bioassay to 
yield a calculated prion titer.  The bioassay inoculum was a brain homogenate pooled from six 
terminal experimentally inoculated WTD (cervid brain pool 6; CBP6) that were confirmed 
PrPCWD positive by western blot prior to pooling.  Transgenic mice engineered to express the 
cellular cervid prion protein were inoculated intracerebrally with a dilution of the CBP6 
extending from 1.0% to 0.00001% weight per volume (Figure 5a).  Using Reed-Muench 
calculations, the mouse bioassay LD50 was calculated to be a 10-5 dilution, the equivalent of 
3.33 x 106 LD50/gram  of brain tissue (23).  The CBP6 dilutional series linear range of RT-QuIC 
amyloid formation rates extended from 10-4 to 10-6 and was fit with a semi-log linear regression 
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line (Figure 5b).  The equation of the semi-log fit line relates RT-QuIC amyloid formation rates 




Figure 3.5 Endpoint dilution bioassay and RT-QuIC quantification of a CWD+ brain 
sample 
(a) Percent mortality of cervidized transgenic mice that developed terminal CWD.    The 
dashed vertical line indicates the LD50 which is calculated to be a 10-5 dilution or 3.33 x 106 
LD50/g of brain tissue.   
(b) RT-QuIC rates of bioassay inoculum dilutional series.  The solid curve represents the RT-
QuIC amyloid formation rates (in LD50 units).  The linear range extended from 10-4 to 10-6.  A 
semi-fit log line (red) was extrapolated from the linear range and used to relate y (rate of 
amyloid formation) to x (LD50).  The equation of this line, in the form y=m log(x) + b, was 
used for FPE quantification displayed in Table 2.  Each point represents the mean and SEM of 





Quantification of prion-related seeding activity in FPE tissues 
The correlation of FPE- RT-QuIC rates with PrPCWD immunoreactivity in pre-clinical 
WTD (Figure 4) led us to estimate prion seeding activity in FPE samples by extrapolation to the 
RT-QuIC reaction rate standard curve derived from a bioassayed CWD brain pool as previously 
described (17).  To establish the standard curve, we used a semi-log linear regression equation 
defined as: amyloid formation rate = 0.04073 log (sample LD50) + 0.1633.  Based on the RT-
QuIC amyloid formation rate we were able to calculate the LD50 equivalents in each gram of 
FPE tissue using the defined equation (16).  For example, the estimated PrPCWD prion seeding 
activity in 1 gram of FPE tonsil from a 4 MPI WTD is calculated to be 3039.6 LD50.  The 
estimated LD50 per gram of FPE tissue in the subclinical WTD samples analyzed in Figure 4 are 
listed in Table 2.  By correlating IHC detection and the RT-QuIC seeding rates in the FPE 
samples tested, we were able to consistently detect moderate IHC staining in samples with 
greater than 200 LD50/g of FPE tissue.  When comparing PrPCWD detection by IHC and RT-
QuIC, we determined that RT-QuIC could detect as little as 39 LD50/g of tissue whereas the 
apparent threshold for detection by IHC examination was 50 LD50/gram.  This indicated that FPE 
RT-QuIC had a greater sensitivity than IHC alone for detecting CWD prion infection; however, a 
larger data set is needed to make a more definitive comparison and quantify the differences in 
sensitivity.  Estimates of prion burdens in FPE samples also enable biological characterization of 
early CWD prion infection previously unavailable using IHC analysis alone.  For example, FPE 
tissues collected during subclinical CWD infection (2 MPI to 4 MPI) demonstrated that tonsils 
consistently accumulated a higher CWD prion burden when compared to retropharyngeal lymph 
nodes.  Likewise, the lymphoid tissues examined at 4 MPI contained at least a 10-fold greater 
LD50/gram PrPCWD deposition in the same tissues on average when compared to 2 MPI.  These 
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observations suggest interesting insights into the early pathogenesis of CWD; however, a larger 
sample size is necessary to draw definitive conclusions.   
Table 3.2 The estimated LD50/gram of FPE samples. 
 
WTD Tonsil Retropharyngeal LN 
1171 (4 MPI) 3.04 x 103 6.49 x 102 
1201 (4 MPI) 1.66 x 103 1.09 x 103 
1215 (4 MPI) 9.60 x 103 1.57 x 103 
1148 (2 MPI) 2.32 x 102 3.95 x 101 





We describe a method for detection and semi-quantification of prion amyloid seeding 
activity in microtome sections of fixed paraffin-embedded tissues.  Consistent with previous 
formalin fixed paraffin-embedded tissue studies analyzing prions by western blot or paraffin-
embedded tissue blot we demonstrate that prion amyloid seeding is maintained throughout the 
tissue aldehyde cross-linking, dehydrating, lipid extracting, and paraffin embedding histological 
processes (9,11).  The FPE RT-QuIC method makes possible the analysis of archived samples 
when only fixed paraffin-embedded tissues are available and minimizes the sampling differences 
encountered when separate fixed and frozen tissue samples are collected and examined.  The 
additional semi-quantitative information provided by FPE RT-QuIC allows more precise 
investigations into PrPCWD accumulation by tissues compared with subjective IHC scoring of 
mild/moderate/marked or lymphoid follicle counts. We have demonstrated the application of this 
method with a small observational study of deer early in their CWD disease progression.  
An interesting observation of FPE RT-QuIC analysis of obex samples in Figure 2 was a 
shift in the range of detection.  Previous RT-QuIC studies of frozen brain samples have 
consistently demonstrated an inability to detect seeding activity in 10-1 to 10-3 dilutions (16,22).  
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This is presumed to be due to inhibitors present in brain homogenates that are diluted out or 
minimized in smaller dilutions, permitting the amyloidogenesis from rPrPC reaction to occur.  
Investigations identifying the biochemical nature of these amyloid seeding inhibitors in brain are 
ongoing.   
The correlation between IHC deposition, RT-QuIC amyloid seeding rate, and the disease 
course expressed as MPI is clear.  Small differences in tissue amyloid seeding rates between 
animals collected at the same time point are expected due to biological variability.  Importantly, 
detection of PrPCWD seeding activity in lymphoid tissues of preclinical WTD with no or minimal 
detectable PrPCWD by IHC suggests either greater sensitivity provided by RT-QuIC amplification 
or the presence of prion conformers that are sensitive to protease treatments used during IHC to 
abolish PrPC background (24).   Likewise, protein misfolding cyclic amplification analyses of 
some tissues in CWD-infected WTD have shown a contrast between amplifiable prion 
enciphering activity and detection of PrPCWD in tissues by IHC (12).  Further analysis with a 
larger data set is needed to accurately compare the diagnostic detection sensitivities and 
specificities of RT-QuIC and IHC.  As with IHC, the degree to which the amyloid seeding 
activity measured by RT-QuIC is infectious is unknown.  Here, we report on FPE RT-QuIC as a 
means to identify prion-derived amyloid seeding activity in fixed tissue and use this information 
to detect prion infection.  This information can then be used, if desired, to estimate tissue prion 
burden by extrapolation to a bioassayed reference sample.   
Building on previous work, we used the mathematical relationship between PrPCWD seed 
concentration and the amyloid formation rate to estimate PrPCWD concentration in tissues (16,17).  
The RT-QuIC quantification method we applied is consistent with previous literature that based 
quantification on endpoint dilution (14) and quantitative PMCA that demonstrates initial PrPCWD 
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seed determines the amplification round of detection (25).  In addition, the IHC staining results 
correlated well with RT-QuIC rates, further validating the relationship between amyloid seeding 
rates and concentration of prions in the sample.  The RT-QuIC amyloid seeding reaction, which 
is consistent across various sample types, requires the presence of a conversion-competent prion 
seed to initiate amyloid formation.  Bioassay data provides information on the lethality of the 
tested sample that is presumed to correspond to the prion burden of the inoculum.  Thus, we can 
estimate the prion burden and lethality of a sample, such as FPE tissues, by extrapolating to the 
bioassay data.  Of course this remains an approximation since the relationship of seeding activity 
and infectivity would be expected to vary with tissue, prion strain, RT-QuIC substrate sensitivity, 
and inhibitors that may be present, especially at low dilutions.  Additional studies are needed to 
more closely quantify the infectivity and lethality of FPE RT-QuIC seeds and amyloid products. 
Frozen lymphoid tissue homogenates likely contain a variety of prion aggregation states as has 
previously been demonstrated in brain homogenates (26,27).  It is not known whether this 
aggregation diversity is maintained throughout the FPE extraction process or if a single 
aggregate type or conformation is preferentially being selected.  We included multiple 
experiments and replicates in our RT-QuIC analysis to mitigate uneven distribution of prion 
seeds in our samples and assay variability.  It is also plausible that a small fraction of prion 
content is lost through the FPE extraction process. The one log lower upper limit of detection in 
FPE brain and retropharyngeal lymph nodes (Figures 2 and 3) could reflect these factors.  If this 
is the case, our mathematical calculations may be underestimating the true prion seeding 
concentration.  Despite these limitations, the FPE RT-QuIC quantification method still provides 
a useful means of estimating prion burden in diverse tissues when animal bioassays are 
precluded by large sample numbers or financial feasibility.   
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 There is little to no evidence at present that RT-QuIC generates infectious prions.  
However, Sano et al. have reported bioassay of amyloid fibrils generated by the first round of 
RT-QuIC reactions seeded with infectious brain homogenate induced prion-specific disease 
when inoculated into wild-type mice (28).  However, amyloid products from additional rounds of 
RT-QuIC did not demonstrate any infectivity.  Lack of infectivity in amyloid fibrils generated 
from recombinant PrPC is not unique to RT-QuIC.  Amyloid fibrils produced by protein 
misfolding cyclic amplification using recombinant PrPC substrate require polyanionic cofactors, 
such as RNA or specific lipids, to demonstrate infectivity in mouse bioassay (29,30).  Possible 
reasons for lack of infectivity of RT-QuIC products include the use of truncated rPrPC as the 
substrate and absence of post-translational modifications, including glycosylation (31).  
 In summary, we present a rapid and simple method of PrPCWD extraction from fixed 
paraffin embedded tissues and analysis for prion amyloid seeding activity using RT-QuIC.  We 
believe this method can facilitate quantitative and correlative investigations of kinetics and 
pathogenesis during early and carrier states of prion diseases and potentially other protein 
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The normal cellular prion protein (PrPC) resides in outer membrane lipid rafts and 
conversion from PrPC to the pathogenic misfolded form is believed to occur at this location.  
Once misfolding occurs, monomers of the pathogenic isoform can polymerize into highly stable 
amyloid fibrils.  In vitro assays have demonstrated an intimate association between prion 
conversion and lipids, specifically phosphatidylethanolamine, which is a critical cofactor in the 
formation of synthetic infectious prions.  In the current work, we demonstrate an opposing 
property of lipids, the ability to inhibit amyloid formation i  vitro.  The amyloid seeding assay, 
real-time quaking-induced conversion (RT-QuIC), was used to investigate whole brain lipid 
effects on prion amyloid formation.  An alcohol based extraction technique was used to remove 
the lipid content from terminal chronic wasting disease (CWD)-infected white tailed deer brain 
homogenates.  Eliminating lipids increased the sensitivity of RT-QuIC detection of CWD in 
brain samples one hundred-fold.  Conversely, addition of brain-derived lipid extracts to CWD 
prion samples inhibited amyloid formation in a dose-dependent manner.  Brain-derived lipids 
also inhibited prion amyloid formation in RT-QuIC reaction seeds derived from lymphoid 
tissues.  Subsequent lipid analysis demonstrated the inhibitory property was restricted to brain 
polar lipids.  This is the first demonstration that a fraction of brain derived lipids directly inhibit 
prion amyloid conversion in vitro and highlights the diverse roles lipids play in the prion 
conversion process.  Future experiments aim to identify the lipid classes or individual lipid 





 The normal cellular prion protein, PrPC, is intimately associated with the outer lipid 
bilayer of the plasma membrane.  PrPC is located within detergent-resistant lipid rafts and 
anchored to the outer membrane through a C-terminal GPI anchor (1-3). This cellular location is 
believed to be crucial for the conformational misfolding that creates the pathogenic isoform of 
prion diseases (4,5).  The PrPC pathogenic conformational change to PrPRES has been shown to 
occur at the cell surface and disruption of lipid rafts, and thus dispersal of PrPC, prevents prion 
infection in cultured neurons (6-8).  In addition, studies using recombinant PrPC to isolate co-
factors to create a de novo infectious prion have identified lipids as a facilitating this pathogenic 
conversion (9).  Phosphatidylethanolamine (PE), in particular, has been isolated as an efficient 
co-factor of prion conversion in every animal species examined (10).   
 RT-QuIC is an amyloid seeding assay that utilizes prion amyloid oligomers or fibrils as 
the seed to initiate amyloid formation and elongation with recombinant PrPC (rPrPC) as the 
substrate (11,12).  Similar to other assays using rPrPC, amyloid conversion in RT-QuIC is 
influenced by cofactors and inhibitors present in the test sample milieu.  Previous reports 
(personal and multiple investigators’ observations) have consistently demonstrated high 
concentrations of brain homogenate are unable to seed RT-QuIC reaction due to presumed 
inhibitors of the amyloid formation reaction (12-14).  To analyze brain homogenates for PrPRES 
seeding activity, samples must be diluted to 10-3 or 10-4 for initial RT-QuIC detection and display 
a linear dilution range from 10-4 to 10-7 which is consistent with removal of reaction inhibitors.  
The identification of these endogenous amyloid formation inhibitors present in certain sample 
types may not only enhance PrPRES detection by RT-QuIC but also illuminate biologic features 
of prion conversion.   
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Our methodology developed to analyze fixed paraffin-embedded tissues using RT-QuIC 
(FPE RT-QuIC) revealed the ability to detect amyloid seeding activity at higher concentrations, 
10-1 and 10-2 dilutions (15), than has previously been reported for brain homogenates.  Here, we 
endeavored to identify the components of brain homogenate responsible for inhibiting the RT-
QuIC amyloid formation reaction.  We demonstrate endogenous lipids present in brain 
homogenate can inhibit RT-QuIC amyloid formation, in contrast to the prion conversion cofactor 
role previously reported.  Our data suggests prion conversion in vitro is guided by a balance of 





Cervid tissue samples:  
 Brain and lymph node samples used in experiments were harvested from white-tailed 
deer experimentally inoculated intranasally with chronic wasting disease (CWD) positive brain 
material (CWD+) or CWD negative brain material (CWD-) as a negative control (16).  All 
CWD+ animals were allowed to progress to terminal disease prior to euthanasia and necropsy.  
At necropsy, all tissues were collected with individual prion-free instruments to avoid cross-
contamination and divided into sections for freezing or fixing.  Frozen tissue pieces were stored 
at -80o C until use.  Ten percent weight per volume tissue homogenates in 1xDPBS (Life 
Technologies) were created using zirconium oxide beads and a Blue Bullet BlenderTM (N xt 
Advance) tissue homogenizer.    
Recombinant Syrian hamster PrPC protein substrate purification: 
 Purification of recombinant truncated Syrian hamster PrPC (residues 90-231) (SHrPrP) 
used as substrate in RT-QuIC was performed as previously described (15,17).  BL21 Rosetta 
(Novagen) Escherichia coli containing the truncated protein construct were cultured from a 
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glycerol stock at 37°C in lysogeny broth (LB) media with the selection antibiotics kanamycin 
and chloramphenicol to express SHrPrP until the culture optical density at 600 nm (OD600) 
reached at least 2.5.  E.coli cell lysis was carried out using BugbusterTM eagent supplemented 
with LysonaseTM (EMD Biosciences) according to the manufacturer recommended protocol.  
Inclusion bodies were harvested by centrifugation at 15,000 x g and dissolved in solubilization 
buffer (8M guanidine hydrochloride, 100 mM Na2HPO4) prior to application to NiNTA flow 
resin (Qiagen) that had been previously equilibrated with denaturation buffer (6M guanidine 
hydrochloride, 100 mM Na2HPO4, 10mM Tris, pH 8.0).  The NiNTA resin-SHrPrP was loaded 
onto a XK16-60 column (GE Healthcare) and purified using a Bio-Rad DuoflowTM FPLC.  To 
induce protein refolding, a gradient from denaturation buffer to refolding buffer (100 mM 
Na2HPO4, 10mM Tris pH 5.5) was applied.  Refolding was followed by a gradient from 
refolding to elution buffer (100mM Na2HPO4, 10 mM Tris, 0.5 M imidazole) and fractions from 
the elution peak were pooled and dialyzed against two 4L changes of buffer (20mM NaH2PO4, 
pH 5.5) overnight.  Final protein concentration was calculated by measuring the A280 and using 
a coefficient of extinction of β5,900 in Beer’s Law.  Purified SHrPrP was stored at 4°C until use.   
Real-time quaking induced conversion (RT-QuIC): 
 RT-QuIC was performed as previously described (17,18).  Tissue homogenates and 
precipitated proteins with lipids were diluted in 0.1% sodium dodecyl sulfate (SDS)/1xPBS to 
the desired concentration.  The RT-QuIC reaction was performed by a ding β μL of diluted 
sample to a buffer containing 20mM NaH2PO4, 320mM NaCl, 1.0 mM EDTA, 1mM Thioflavin 
T (ThT) and 0.1 mg/mL SHrPrP in one well of a black, optical-bottom 96-well plate (Nunc).  
RT-QuIC experiments were carried out in a BMG Labtech PolarstarTM fluorometer with cycles 
of 1 minute shaking (700 rpm, double orbital) followed by 1 minute rest, repeated for 15 
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minutes.  ThT fluorescence was read (excitation 450 nm, emission 480 nm, gain of 1700) at the 
conclusion of each 15 minute shake/rest cycle and each well was measured with 20 flashes per 
well with an orbital average of 4.  Each RT-QuIC experiment was performed for a minimum of 
100 cycles.  RT-QuIC amyloid formation was determined to be positive if the fluorescence 
exceeded a threshold determined to be 5 standard deviations above the average baseline 
fluorescence.  RT-QuIC amyloid formation rates in RT-QuIC were analyzed by calculating the 
inverse of the time to threshold.   
Lipid extraction from brain homogenates:  
 Lipids were extracted from 10% brain homogenates using a modification of the Folch 
method (19).  Briefly, 100 μL of a 10% brain homogenate was incubated with 900 μL of 100% 
ethanol at room temperature for 5 minutes.  Following incubation, brain homogenate-alcohol 
solutions were centrifuged at 15,000 x g for 5 minutes to precipitate proteins.  The ethanol 
supernatant was saved and the alcohol extraction process was repeated.  Pooled ethanol 
supernatants were dried under a stream of nitrogen gas prior to resuspension in 100 μL a 
chloroform/methanol solution (2:1) to maintain original concentration (Figure 4.1A).  Extracted 
lipids in the chloroform/methanol solvent were added to precipitated proteins from tissue 
samples.  Commercially purchased total brain lipid extract and polar brain lipid extracts (Avanti 
Polar Lipids) were dissolved in chloroform/methanol solvent (2:1) immediately prior to use to 
create the desired weight/volume concentration and added to precipitated proteins from tissue 





Figure 4.1 Overview of methods.  
A. Lipid extraction from 10% brain homogenate.  Brain homogenate was treated with 100% 
ethanol (EtOH) and proteins pelleted by centrifugation.  The ethanol supernatant and its 
dissolved contents were removed and dried under a stream of nitrogen gas.  B. Sample 
preparation for RT-QuIC.  Dried alcohol extracts were resuspended in chloroform/methanol 
solvent.  Resuspended extracts were combined with alcohol precipitated proteins (in A) for use 
in the RT-QuIC assay.   
 
Isolation of polar lipids 
 Total brain lipid extracts were separated into polar and neutral/non-polar fractions with 
acetone precipitation.  Approximately 20-30x volume of acetone was added to dried total lipid 
extracts and incubated on ice for 1 hour.  The acetone-lipid mixture was centrifuged at 15,000 x 
rpm for 5 minutes to pellet polar lipids.  The entire procedure was repeated and acetone 
supernatants combined.  Lipid pellets and acetone supernatants were dried under a stream of 
nitrogen gas prior to resuspension in chloroform/methanol solvent (2:1) in volumes equivalent to 
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the starting material to maintain physiologic concentrations.  Acetone fractionated lipids were 
added to alcohol-precipitated proteins to seed the RT-QuIC reaction as previously described.   
Fixed paraffin-embedded (FPE) RT-QuIC 
 FPE tissue blocks were processed and proteins extracted as previously described (15).  
Briefly, a microtome (Leica) was used to cut 8-10 μm thick paraffin-embedded tissue-wax curls 
from paraffin blocks.  Tissue-wax curls were treated sequentially with xylene to remove paraffin, 
a series of graded alcohol washes (100%, 95%, and 70%) to rehydrate the tissue sections, and a 
final 1xPBS wash to remove any remaining solvents with a five minute centrifugation at 15,000 
rpm to pellet tissue pieces between each wash step.  Rehydrated FPE tissue samples were 
homogenized in 1xPBS to create a standard 10% weight per volume using a bead homogenizer 
as described above.  FPE homogenates were diluted in RT-QuIC dilution buffer (0.1% 
SDS/1xPBS) to the desired concentration prior to RT-QuIC analysis.   
Western blotting of RT-QuIC products 
 Protease resistant amyloid products of the RT-QuIC reaction were detected by western 
blotting.  RT-QuIC products were collected at the completion of the assay by washing each well 
with the RT-QuIC reaction buffer and combining replicates seeded by the same sample.  Nine μL 
of collected RT-QuIC products were digested with proteinase K (PK) at a final concentration of 
1 μg/mL and incubated at γ7°C for γ0 minutes with shaking followed by 45°C for 10 minutes 
with shaking.  Samples were mixed with reducing agent (10x)/LDS sample buffer (4x) 
(Invitrogen) at a final concentration of 1x, heated at 95°C for 5 minutes then electrophoresed 
through a NuPAGE 10% Bis-Tris gel (Invitrogen) at 135 V for 1.5 hours.  Proteins were 
transferred to a polyvinylidene fluoride (PVDF) membrane using the Transblot TurboTM system 
(Bio-Rad) following manufacturer instructions.  The membrane was loaded into a pre-wetted 
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SNAP i.d. blot holder (Millipore) then sequentially blocked with blocking buffer (Blocker 
Casein in TBS [Thermo-Scientific] and 0.1% Tween-20 [Sigma]) for 3 minutes and probed with 
antibody BAR224 (Cayman Chemical) conjugated to horseradish-peroxidase (HRP) diluted to 
0.βμg/mL in blocking buffer for 10 minutes.  Antibody was removed by vacuuming through the 
membrane using the SNAP i.d. system (Millipore) and the membrane was washed three times 
with 30 mL wash buffer (50% Blocker Casein in TBS, 50% 1X TBS, 0.1% Tween-20) with 
continuous vacuum.  The membrane was developed with ECL-Plus Western Blotting Detection 





Identification of lipids as inhibitors of prion amyloid formation 
Studies performed when developing the FPE RT-QuIC method demonstrated RT-QuIC 
amyloid seeding at higher concentrations of FPE samples than had been previously possible (15).  
Amyloid seeding in FPE brain derived samples had a linear detection range extending from 10-1 
to 10-7 whereas non-FPE frozen brain homogenate samples displayed a linear range extending 
from 10-4 to 10-8 due to inhibitors at high concentrations consistent with published literature 
(Figure 4.2A) (12,13).  In contrast, retropharyngeal lymph node homogenates did not contain 
inhibitors at high tissue concentrations and successfully seeded RT-QuIC amyloid formation 
(Figure 4.2B).  These observations indicated a component of brain homogenates not present in 
lymph node homogenates could inhibit prion enciphered amyloid formation and the FPE sample 




Figure 4.2 RT-QuIC dilutional series of FPE and frozen tissue homogenates 
A.  RT-QuIC dilutional series of FPE and frozen brain homogenate samples.  The FPE 
protocol allowed prion-enciphered RT-QuIC amyloid formation with higher sample seed 
concentrations, extending the linear range of detection from 10-1 to 10-7 while inhibitors in 
higher concentration of brain homogenates prevented amyloid formation (highlighted by 
yellow box).   
B.  RT-QuIC dilutional series of FPE and frozen lymph node homogenate samples.  In contrast 
to brain (A), higher concentrations of frozen lymph node homogenates are able to seed the RT-
QuIC reaction similar to FPE lymph node homogenates (yellow box) allowing detection at all 
dilutions examined and displays a linear range from 10-2 to 10-6.   
 
To determine which component of our FPE RT-QuIC protocol was responsible for 
removal of RT-QuIC reaction inhibitors in brain samples, we isolated and tested each step of the 
FPE sample preparation protocol.  To analyze the effects of tissue fixation on RT-QuIC amyloid 
seeding ability, a frozen section of CWD+ obex was fixed in paraformaldehyde-lysine-periodate 
fixative (PLP) for 48 hours prior to homogenization.  The PLP CWD+ brain homogenate and 
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standard frozen brain homogenates were further treated with either a combination of 
xylene/alcohol or alcohol alone prior to seeding RT-QuIC (Figure 4.3).  CWD+ frozen brain 
homogenate contained the greatest amount of reaction inhibitors, demonstrated by no amyloid 
formation at 10-1 dilution and a slower rate at 10-2 dilution.  CWD+ PLP-fixed brain homogenate 
(Figure 4.3, green line) had amyloid formation kinetics similar to frozen brain homogenate, with 
no amyloid formation at a 10-1 and a slower rate of formation at a 10-2 dilution.  These results 
indicated PLP fixation alone was not responsible for removal of amyloid formation inhibitors.  
Treatment of both the PLP-fixed and frozen brain homogenates with both xylene/alcohol steps 
demonstrated similar kinetic curves with amyloid seeding detection at 10-1 and 10-2 dilutions 
(Figure 4.3, black and red lines).  Both samples had rates of amyloid formation that were 
indistinguishable from CWD+ FPE brain homogenate (Figure 4.3, blue line).  To determine 
which of the xylene and alcohol solvents removed inhibitors, CWD+ frozen brain homogenate 
was treated with a series of alcohol dilutions.  This sample preparation produced the highest rate 
of amyloid formation and displayed a linear dilution range from 10-1 to 10-3 (Figure 4.3, orange 
line).  A dilutional series of frozen CWD+ brain homogenate treated with alcohol (Figure 4.3B) 




Figure 4.3 RT-QuIC detection of prion amyloid seeds following different solvent 
treatments.  
A. RT-QuIC prion detection following FPE protocol solvent treatments.  CWD+ brain 
homogenate (purple) prion seeding showed inhibition at 10-1 and 10-2 dilutions.  PLP fixation 
(green) of CWD+ sample showed inhibition at 10-1 dilution.  Treatment of CWD+ brain 
homogenate (black) and PLP-fixed CWD+ brain homogenate (red) with xylene and alcohol 
solvents allowed amyloid seeding at all dilutions comparable to FPE CWD+ sample (black).  
CWD+ brain homogenates treated only with alcohol (orange) allowed prion-seeded detection at 
all dilutions and had the highest rates of amyloid formation.   
B. RT-QuIC dilutional series following alcohol treatment.  The alcohol treatment removed brain 
homogenate inhibitors at high concentrations and allowed prion-seeded amyloid formation from 
10-1 to 10-7.   
 
 Alcohols are known solvents of lipids (20).  Thus, we hypothesized brain-derived lipids 
were inhibiting the RT-QuIC amyloid formation reaction.  To test this hypothesis, a commercial 
preparation of total brain lipid extract was applied to CWD+ alcohol precipitated samples at 
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approximate physiological concentrations (21).  The addition of commercial lipids inhibited 
amyloid formation in a dose dependent manner with 6% commercial lipids in 
chloroform/methanol solvent completely inhibiting all sample dilutions tested and 3% 
commercial lipids only inhibiting amyloid formation at the 10-1 dilution (Figure 4.4A).  The 
negative control of chloroform/methanol solvent displayed minor inhibition at the 10-1 dilution 
but did not abolish amyloid formation.  These results confirmed brain derived lipids can inhibit 
the RT-QuIC amyloid formation reaction.     
Since the detection of amyloid formation in RT-QuIC relies on thioflavin T binding 
amyloid structures and subsequent fluorescence we wanted to ensure the lack of RT-QuIC 
fluorescence signal in our experiments was due to lack of seeded amyloid formation and not 
thioflavin T binding.  To test this, RT-QuIC reaction products from Figure 4.4A were examined 
by western blot for prion-enciphered PK resistant amyloid material.  Replicates from the 10-1 
dilution seeded reactions were pooled and treated with 10 μg/mL PK solution prior to western 
blotting.  PK resistant material was only observed in the CWD+ chloroform/methanol solvent 
seeded reaction (Figure 4.4B) which corresponded to the positive fluorescence signal detected by 
RT-QuIC.  These results confirmed total brain lipids were inhibiting prion-seeded amyloid 




Figure 4.4 Total brain lipid extracts inhibit prion-enciphered amyloid formation 
A. RT-QuIC of CWD+ seeds with commercial total brain lipid extracts.  The addition of total 
brain lipids inhibited RT-QuIC in a dose dependent manner.  The lipid delivery solvent, 
chloroform/methanol, had a minimal effect on the RT-QuIC reaction.   
B. Western blot of RT-QuIC reaction products from 10-1 seed concentration.  The western blot of 
RT-QuIC products from the experiment in A only detected PK-resistant prion-enciphered 
amyloid material from samples seeded with CWD+ brain-3% total lipids (red arrow).  This result 
corresponded with the fluorescence observed at this seed dilution (green).     
 
 Next, we sought to assess the ability of brain extracted lipids to inhibit prion-seeded RT-
QuIC amyloid formation in lymph node homogenates that naturally do not contain the same 
inhibitors.  First, we extracted brain lipids from CWD-negative white-tailed deer brain 
homogenate and added these deer origin brain lipids to alcohol precipitated CWD+ brain protein.  
We observed similar amyloid formation kinetics as frozen CWD+ brain homogenates (Figure 
4.5A).  This ensured our alcohol extraction technique could isolate brain lipids and transfer them 
to other samples.  We then added deer origin brain lipids to alcohol-precipitated CWD+ 
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retropharyngeal lymph node samples.  Prion seeded amyloid formation in the lymph node treated 
with deer-origin brain lipids was inhibited at 10-1 dilution whereas the alcohol-precipitated and 
frozen homogenate of the same origin lymph node displayed amyloid seeding at the same 
dilution (Figure 4.5B).  This further demonstrated brain-derived lipids alter prion-seeded 
amyloid formation kinetics in RT-QuIC.   
 
Figures 4.5 Extracted deer brain lipids can inhibit RT-QuIC 
A. Alcohol-extraction can remove white-tailed deer brain lipids.  The alcohol extraction protocol 
was used to remove lipids from CWD- brain homogenate.  The removed lipids were added to 
alcohol precipitated CWD+ brain homogenate (green) and caused inhibition at 10-1 nd 10-2 
dilutions with amyloid formation kinetics comparable with 10% brain homogenate (blue).    
B. Total brain lipids inhibit lymph node seeded RT-QuIC.  Brain lipids extracted from CWD- 
brain homogenate were added to alcohol-precipitated lymph node prion seeds (green).  The 
addition of lipids inhibited RT-QuIC prion-seeded amyloid formation at 10-1 dilution where 





Polar lipids inhibit prion-seeded amyloid formation 
 Lipids can be divided into classes based on their polarity.  We used acetone precipitation 
to separate endogenous brain lipids into polar and neutral/nonpolar fractions and tested these 
groups for RT-QuIC inhibitor activity.  Alcohol precipitated CWD+ brain seeds treated with the 
acetone lipid pellet containing polar lipids were inhibited at the 10-1 concentration (Figure 4.6A) 
but displayed amyloid formation at greater dilutions.  In contrast, when the same CWD+ brain 
seeds were treated with the acetone supernatant containing neutral and nonpolar lipids amyloid 
formation occurred at all dilutions, albeit with a slower formation rate at the 10-1 dilution.  To 
confirm these results, CWD+ brain seeds were treated with commercially prepared polar lipids at 
physiologic concentrations.  The addition of polar lipids inhibited prion-seeded amyloid 
formation in a dose dependent manner with 5% polar lipids showing complete inhibition at all 
dilutions, with 0.5% inhibiting only the 10-1 concentration of prion seeds (Figure 4.6B).  These 
results indicated polar lipids contain the majority of lipid amyloid forming inhibitory properties 





Figure 4.6 Polar lipids inhibit prion seeded amyloid formation 
A. Acetone fractionation of total brain lipid extracts.  Acetone was used to fraction total brain 
lipids into polar lipids, contained in the pellet, and non-polar lipids, contained in the supernatant.  
The addition of the pelleted lipid fraction to CWD+ seeds inhibited RT-QuIC at 10-1 dilution 
whereas addition of the acetone supernatant caused minor inhibition of RT-QuIC at the same 
dilution.   
B. Commercial polar lipids inhibit RT-QuIC.  Adding commercially prepared polar lipids to 
CWD+ seeds caused inhibition of amyloid formation in a dose-dependent manner with complete 
absence of amyloid formation at 5% lipid concentration and no inhibition at a 0.5% lipid 










 PrPC, like other GPI-anchored surface proteins, resides in lipid rafts within the outer 
leaflet of the cell membrane, a location that has been shown to be essential for the prion 
conversion process (2,22,23).  Lipid raft microdomains are enriched in sphingolipids and 
cholesterol to maintain structural integrity and coalesce signaling molecules (24) and alterations 
in these components, such as disrupting cellular cholesterol homeostasis (25) or treatment with 
the enzyme filipin (26), decreased surface PrPC and resulted in decreased formation of PrPRES.  
In contrast to cholesterol, sphingomyelin depletion in N2a cell membranes caused an increase in 
PrPRES through an unknown mechanism (27).  The membrane lipid environment has been shown 
to directly promote prion propagation by destabilizing the C-terminal domain, facilitating PrPRES 
conversion and fibril formation (28,29).  These studies highlight the important role lipids play in 
prion propagation at a cellular level.  Prion diseases also alter lipid homeostasis at the whole-
organism level.  A transgenic mouse model of scrapie has shown alterations in lipid 
compositions in the brain at terminal disease (30).   
Many of the lipid-protein interactions implicated in prion diseases mirror those described 
in the pathogenesis of amyloid- (A ) aggregation in Alzheimer’s disease.  Like PrPC, amyloid-  
precursor protein (APP) is an integral plasma membrane protein, although it is characterized by a 
transmembrane domain instead of a GPI anchor (31,32).  The lipid environment surrounding 
APP and the secretase enzymes that perform the post-translational processing can impa t the 
form of A  produced at membranes; when APP has been isolated from lipid rafts it was more 
likely to be associated with -secretase cleavage and amyloidogenic forms (33-36).  The 
influence of lipid raft location on A  formation is also determined by cholesterol and an increase 
in membrane cholesterol shifts toward A  aggregations (37,38).  Similar to the effect on the 
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prion conversion process, membrane lipids can also destabilize the A  conformational structure 
and induce the protein to acquire an additional -sheet which increases fibrillization and 
aggregation (39,40).  With the similarities in pro-amyloid protein-lipid interactions in prion and 
Alzheimer’s disease, it would be interesting to investigate whether the inhibitory lipid function 
we identified can cross protein species.   
Not only does the lipid bilayer influence protein misfolding but may also contribute to 
prion pathology as toxic nonfibrillar prion oligomers have been shown to directly interact with 
membrane lipids (41,42).  Proposed mechanisms of toxicity include prion oligomer membrane 
insertion as pores or channels similar to A  in Alzheimer’s disease pathology (43,44); detergent-
like activity similar to islet amyloid precursor protein in diabetes pathology (45); or prion 
fibrillization on the surface of lipid rafts leading to a functional loss of membrane domain 
organization (41).  These toxic interactions appear to depend on the composition of the lipid 
bilayer.  The ability of amyloid- to form pores and fragment lipid bilayers depended on the 
presence of gangliosides (44).  Studies altering the content of anionic cellular membrane lipids 
induced a switch in prion oligomer membrane interactions from micelle formation to increased 
formation of fibrils on lipid microdomains (41).  Membrane lipids, specifically 
phosphatidylethanolamine, have been shown to be a cofactor in prion protein conversion in vitr  
(10) by facilitating protein structural changes (46).  Taken together, these studies and the 
presented data illustrate a variety of roles for lipids in the prion conversion process and suggest 
the composition of the lipid environment may be a crucial component of prion pathology.    
 Our western blot data suggests that polar lipids interfere with the prion conversion 
process; however, the mechanism of how this is accomplished needs further investigation.  Other 
molecules identified as potential prion disease therapeutics that also limit prion conversion can 
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provide insight into potential mechanisms of action.  Glycosaminoglycans and the azo dye 
Congo red mechanistically decrease PrPRES formation by competitive inhibition.  Both have been 
shown to bind PrPC and decrease its availability for PrPRES interaction and prion conversion 
(47,48).  Congo red dye has also been shown to hyperstabilize prion amyloid fibrils which 
prevents fragmentation and seeded amyloidogenesis (49,50).   
 Our experiments highlight a potential exciting use of RT-QuIC for investigating 
molecules that can alter prion formation kinetics.  Currently, investigations into potential 
therapeutics are limited to cell culture assays and costly animal bioassays (51).  A modified 
PMCA technique using recombinant protein (10) as well as other amyloid seeding assays have 
previously been used in a limited number of prion conversion cofactor investigations.  We show 
that the different alcohol based solvents used to deliver lipids did not themselves alter RT-QuIC 
amyloid formation kinetics.  Additional study is needed to establish the robustness of RT-QuIC 
when used with a variety of delivery solvents or compounds.  However, the ease and high 
throughput nature of RT-QuIC can facilitate widespread screening for molecules that inhibit 
prion amyloid formation (52).    
In summary, we have demonstrated endogenous brain polar lipids can inhibit prion 
amyloid conversion in vitro.  This is the first identification of an inhibitory function of lipids and 
suggests prion conversion is a balance of pro-conversion and inhibitory lipid molecules.  Future 
avenues of investigation include examining the role the lipid environment plays on the 







 Future experiments aim to parse out which class of endogenous lipids and/or individual 
lipids are responsible for inhibiting amyloid formation.  We plan to use adsorption 
chromatography to separate polar lipids into neutral lipids, glycolipids/ceramides, and 
phospholipids based on their respective solvency and evaluate each lipid class’s influence on 
amyloid formation kinetics.  Once the class type with inhibitory features has been identified, we 
aim to perform mass spectrometry to characterize the lipids present in that fraction.  Following 
this identification, we will purchase individual lipids and test each for the ability to inhibit RT-
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 Through the work presented in this dissertation, I have investigated various aspects of 
prion pathogenesis.  First, I demonstrated the expression of heat shock protein 72 does not alter 
the pathogenesis of prion propagation in murine neuroblastoma cells or C57Bl/6 mice.  Second, I 
mapped the distribution of PrPCWD in the early pre-clinical phase of chronic wasting disease, 
illustrating the progression from oropharyngeal lymphoid tissues to systemic lymphoid tissues 
prior to neuroinvasion.  Third, in the process of investigating early PrPCWD distribution, I 
developed a new technique to detect PrPCWD amyloid seeding activity in fixed paraffin-
embedded tissues using RT-QuIC.  Analysis of RT-QuIC amyloid formation kinetics in these 
samples yielded a semi-quantitative estimate of the prion burden without the need for animal 
bioassay.  Finally, in the process of developing FPE RT-QuIC, I was able to demonstrate that 
endogenous brain lipids can inhibit prion-seeded amyloid formation in RT-QuIC, the first 
identification of such activity in these molecules.   
 Although our investigations of HSP72 function in prion protection yielded negative 
results it still contributes to the prion field by being the first in vivo study of this chaperone-
mediated function.  Several possible reasons were identified as to why prion-chaperone 
interactions are different than other protein-misfolding diseases, including: (1) is there a cellular 
spatial separation between HSP72 expression and prion protein misfolding, (2) do PrPC and 
PrPRES have a binding domain for HSP72, and (3) is the HSP72 expression level too low to be 
therapeutic by limiting HSP72 expression levels to neurons?  Future investigations to further 
understand these negative results might involve, analysis of the binding affinity of HSP72 to 
PrPC and various aggregation forms of PrPRES by specific plasmon resonance (Biacore) 
technology, in vitro co-culture of prion-susceptible cells with HSP72-expressing astrocytes or 
132 
 
microglia, and in vivo prion infection with mice expressing HSP72 in all cell types under control 
of the -actin promotor or limited to specific cell types.  
  In the study of PrPCWD distribution during early CWD disease, I focused on lymphoid 
tissues draining the gastrointestinal tract.  Future investigations will evaluate the remaining 50+ 
tissues collected at necropsy from the same animals to get a whole-animal picture of prion 
distribution during early infection.  To rapidly evaluate this large number of samples, we plan to 
adapt RT-QuIC to an end-point fluorescence read.  In addition to the numerous tissues collected 
at necropsy, excreta samples including saliva and urine, were also collected from the same 
animals.  A more complete picture of prion distribution and shedding potential at these early 
stages of disease are useful in enhancing our understanding of prion pathogenesis and to develop 
therapeutic intervention strategies.   
 The identification of PrPCWD in lymphoid tissues during early CWD infection in deer 
revealed two separate patterns: (1) an initial prion replication phase in oropharyngeal lymphoid 
tissues and (2) a later systemic prion replication phase.  Although we demonstrated all lymphoid 
tissues appear to have the same prion replication kinetics by RT-QuIC analysis, it is unknown if 
the same cell types are involved and if any, which cells are involved in systemic prion spread.  
Potential future studies will type prion-positive cells using double-label immunohistochemistry 
in tissue sections, or, if possible to collect through thoracic duct ligation, analyze lymph over the 
course of early disease for prion-associated cells or lipoprotein molecules.   
 The accurate diagnosis of prion diseases during preclinical disease stages is crucial to the 
management of CWD populations and design of interventional strategies.  The small number of 
samples evaluated as part of our development of FPE RT-QuIC suggested our new methodology 
has greater detection sensitivity than IHC in fixed paraffin-embedded tissues; however, a larger 
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sample analysis is necessary to establish sensitivities and specificities as a diagnostic test.  
Additionally, a large scale assessment of current assays, such as RT-QuIC, TSA-IHC, and End-
point QuIC, would be beneficial in determining their diagnostic application to the preclinical 
disease phase and guide the selection of tests for experimental needs.  Furthermore, the 
identification of PrPCWD seeding activity in FPE samples by RT-QuIC lays the groundwork for 
the development of an i situ amyloid seeding assay using RT-QuIC technology.   
 Finally, the discovery of endogenous brain lipids, specifically polar lipids, as inhibitors of 
prion amyloid formation in vitro is the first identification of RT-QuIC reaction inhibitors and the 
first identification of such an inhibitory function of these molecules.  Future studies aim to 
specify which lipids or class of lipids are responsible for this function by adsorption 
chromatography separation of lipid classes and mass spectrometry to categorize the lipids present 
in our extractions.  Many questions follow from our RT-QuIC lipid observations including: (1) 
does the polar lipid inhibitory property in RT-QuIC apply to other prion species besides CWD, 
(2) can polar lipids inhibit amyloid seeding in general, or is the action specific to prions, (3) what 
are the lipid requirements for prion conversion n vivo? The first question could be addressed 
with RT-QuIC experiments and brain samples available.  The second question requires 
development of amyloid seeding assays, similar to RT-QuIC, that are specific to the other protein 
misfolding diseases.  Development of these assays could also have a greater application beyond 
the evaluation of lipid-protein interactions.  Lastly, the third question could be evaluated through 
lipid membrane models and cell culture.   
In conclusion, the studies presented in this dissertation have contributed to furthering the 
knowledge of prion propagation and pathogenesis.  Moreover, these studies have provided tools 
and established a basis for future investigations into prion and protein misfolding pathogenesis.     
